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 Endogenous nitric oxide (NO) is derived from L-arginine via a chemical reaction catalyzed 
by nitric oxide synthases (NOS). Three NOS isozymes are found in humans: neuronal NOS 
(nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). Over-activation of NOS enzymes 
lead to pathologies due to excessive NO production. In particular, nNOS and iNOS are implicated 
in serious neurodegenerative and inflammatory diseases, and are hence attractive pharmacological 
targets. However, off-target inhibition of eNOS results in adverse effects such as hypertension and 
atherosclerosis. To complicate drug design, the NOS active site sequence is highly conserved 
across isozymes. Most of the currently available NOS inhibitors have been designed through and 
assayed against non-human mammalian NOS isozymes but the recent publication of the human 
nNOS oxygenase crystal structures showed minute differences in structure between human NOS 
and their non-human counterparts. Oxyhemoglobin capture assays were performed to determine 
the specific activity of each NOS isoform and plot the corresponding Michaelis-Menten curves to 
determine their relative affinity towards the substrate L-arginine. These assays, which are 
performed in quadruplicates, show significant difference in the activity of human NOS and non-
human NOS. Furthermore, discrepancies in the Km values of human NOS and non-human NOS 
were observed.  
 Inhibition studies using first generation active site inhibitors were performed in 
quadruplicates to confirm their isoform selectivity as previously determined using non-human 
NOS isoforms. L-arginine based inhibitors L-NMMA, L-ALA and L-NNA were shown to be non-
selective over eNOS. However, the affinity ranking (in terms of Ki) of human NOS toward these 
L-ALA and L-NNA did not agree with the affinity rankings for non-human NOS. The Ki values 
of the cyclic aromatic compound 3-bromo-7-nitroindazole did not vary among isoforms for both 
human and non-human NOS, as previously available data. In contrast, the iNOS selective isoform 
1400W showed significantly higher affinity towards iNOS over nNOS and eNOS. Given these 
preliminary results, the minute differences in sequence and structure between human and non-
human NOS appear to have substantial effects on the selectivity of first generation inhibitors. 
However, it is important to note that these results need to be verified by structural studies, which 




 To determine if human and non-human NOS are affected by calmodulin-binding inhibitors 
differently, inhibition assays were performed with trifluoperazine (TFP) and melatonin. Since both 
of these inhibitors bind CaM instead of NOS, it is expected that their IC50s for human and non-
human NOS isoforms would be similar. Furthermore, the fact that these compounds bind CaM in 
a similar manner suggests that TFP and melatonin would have similar dose-inhibition curves. 
However, only TFP exhibited dose-dependent inhibition of NOS, while melatonin did not inhibit 
NOS at all. In any case, the inhibition assay results for both did not show differences between 
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1. Literature review 
1.1 Nitric oxide physiology 
Nitric oxide (NO) is a signalling molecule that plays a critical role in the maintenance of 
normal physiology in mammals, including humans. NO is small and gaseous, and thus, diffuses 
freely across membranes. Its short half-life allows for its short range of action. Primarily, NO 
induces the conversion of guanosine triphosphate into cyclic guanosine monophosphate (cGMP) 
by binding and activating soluble guanylyl cyclase in the target cell. cGMP is a secondary 
intracellular molecule and it is involved in most physiological pathways, e.g. cardiovascular 
regulation, immune response and neurotransmission. cGMP binds and activates cGMP-dependent 
protein kinase or protein kinase G, which initiates a signalling cascade, the effects of which are 
dose-dependent and tissue-specific.(Alderton, Cooper, & Knowles, 2001) NO functions in 
neurotransmission, cardiovascular regulation and immune response. 
Given its role in normal physiology and short half-life (t1/2 = 5 s), NO is constantly 
produced at low levels in the body, except during disease.(Alderton et al., 2001; Joubert & Malan, 
2011) However, overproduction of NO leads to serious pathological conditions, some of which 
could be fatal. NO overproduction has been implicated in neurodegenerative diseases. It has also 
been shown that high levels of NO causes uncontrolled inflammation. Furthermore, NO can react 
with other physiological compounds to form reactive nitrogen species (RNS) that are detrimental 
to cell growth and development. Peroxynitrite (ONOO-) is an RNS that is highly reactive with 
various biological targets. As such, regulation of NO synthesis is an important field in 
pharmacological research. 
1.2 Nitric oxide synthase 
Endogenous NO is derived from L-arginine via a chemical reaction catalyzed by nitric 
oxide synthase (NOS).(Alderton et al., 2001) There are three known NOS isozymes found in 
mammals: neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS).(Alderton 
et al., 2001) The first two are constitutively expressed, i.e. exist at a constant level at normal 
physiological state, and are sometimes collectively referred to as constitutive NOS 
(cNOS).(Alderton et al., 2001) nNOS is primarily found in the neuronal cells and is involved in 
NO-mediated neurotransmission. eNOS is expressed in endothelial cells and is essential to 
cardiovascular regulation through NO-induced vasodilation.(Alderton et al., 2001) Meanwhile, 
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iNOS expression is induced by inflammatory cytokines during diseased state and is highly linked 
to immune response.(Alderton et al., 2001) NOS enzyme catalysis is activated upon binding of the 
protein cofactor, calmodulin (CaM). 
1.2.1 NOS isoforms, related physiology and pathophysiology 
As mentioned above, there are three known mammalian NOS isozymes and the effects of 
NO signalling are dependent on which NOS enzyme synthesized the NO molecule. The differences 
among nNOS, eNOS and iNOS are discussed in this section. 
1.2.1.1 Neuronal nitric oxide synthase (nNOS) 
As suggested by its name, nNOS is constitutively expressed in neurons of the nervous 
system. Even so, nNOS expression can be affected by neurotransmitter and steroid hormone 
signalling.(Joubert & Malan, 2011) Furthermore, gene regulation may induce nNOS alternative 
splicing, which results in the selective expression of nNOS isoforms: nNOS-α, nNOS-β, nNOS-γ 
and nNOS-µ.(Eliasson, Blackshaw, Schell, & Snyder, 1997; Joubert & Malan, 2011) nNOS-α 
refers to the full-length nNOS peptide. Unlike eNOS and iNOS, the nNOS isozyme has the 220 
amino acid-long PSD-95 discs large/ZO-1 (PDZ; PSD stands for post-synaptic density protein 95) 
homology domain. The PDZ domain mediates the anchoring of nNOS to the neuronal membrane 
and the C-terminus of the N-methyl-D-aspartate (NMDA) receptor.(Alderton et al., 2001) In 
general, nitrergic signalling begins with the activation of the NMDA receptor by the 
neurotransmitter glutamate. NMDA is a ligand-gated calcium channel, whose activation triggers 
an influx of calcium ions. The subsequent increase in intracellular calcium then activates CaM 
proteins. Activated CaM binds and activates nNOS as described before, causing an increase in NO 
production. NO activates soluble GC, causing an increase in intracellular cGMP, which then 
activates PKG. In nitrergic neurons, PKG phosphorylates and activates potassium ion channels. 
Furthermore, since NO can diffuse freely across membranes, it can travel to neighbouring neurons 
and activate the soluble GCs in those cells as well where other ion channels are also activated by 
PKG.(Mukherjee, Cinelli, Kang, & Silverman, 2014; Taqatqeh et al., 2009)  
NO neurotransmission has been implicated in the learning process and memory formation, 
particularly in long-term potentiation (LTP).(Hopper & Garthwaite, 2006; Taqatqeh et al., 2009) 
Increased levels of NO have been shown to improve memory and restore observable LTP in nNOS 
knockout rats.(Hopper & Garthwaite, 2006) However, increased NO production in neurons could 
lead to neurotoxicity and given the free diffusion of NO across membranes, these neuronal deaths 
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are not confined within a single cell only. NO-induced neurotoxicity is linked to neurodegenerative 
diseases such as Alzheimer’s and Huntington’s diseases.(Mukherjee et al., 2014) In both cases, 
neuronal deaths are caused by oxidative damage in cellular organelles due to NO over-excitation. 
In the case of Parkinson’s disease, tyrosine nitration of select proteins causes the formation of 
inclusion bodies that are insoluble and resistant to normal degradation pathways thereby 
preventing normal neuron function.(Mukherjee et al., 2014)  
1.2.1.2 Endothelial nitric oxide synthase (eNOS) 
NO is involved in the maintenance of vascular tone; eNOS constitutively produces low 
levels of NO to balance adrenergic vasoconstriction and prevent hypertension. Under normal 
physiological conditions, eNOS in vascular endothelial cells are stimulated by the parasympathetic 
nervous system through the neurotransmitter acetylcholine (ACh).(Kellogg, Zhao, Coey, & Green, 
2005) ACh binds and activates M3 receptors in endothelial cells, which are Gq-protein coupled 
receptors. Activation of this signalling pathway increases the intracellular calcium concentration, 
which causes the activation of the NOS cofactor CaM.(Kellogg et al., 2005) CaM then activates 
eNOS, as described above, and the NO produced by eNOS freely diffuses into adjacent vascular 
smooth muscle cells, where it activates soluble GC.(Palmer, Ashton, & Moncada, 1988) In this 
case, cGMP binds and inactivates calcium ions, thus causing a decrease in the intracellular calcium 
concentration of vascular smooth muscles. In addition, cGMP activates PKG, which 
phosphorylates and inactivates myosin light chain kinase (MLCK), thereby preventing contraction 
of the smooth muscle cells. Vasodilation reduces the blood pressure. Indeed, exogenous NO, 
derived from nitroglycerin and other nitrates, have been used in the pharmacological treatment of 
hypertension. A caveat, however, is that soluble GC in the vasculature is prone to desensitization 
of NO. As such, NO loses potency if given at doses higher than the physiological levels. To counter 
this, NO production by eNOS is regulated via a negative feedback loop; NO inhibits its own 
production by S-nitrosylation of select tyrosine residues in the eNOS enzyme.(Joubert & Malan, 
2011; Kellogg et al., 2005) This mechanism ensures tight regulation of NO activity in the 
cardiovascular system. NO also inhibits platelet aggregation, which has direct effects on the 
prevention of atherosclerosis and increased blood pressure. 
1.2.1.3 Inducible nitric oxide synthase (iNOS) 
Unlike nNOS and eNOS, iNOS is not constitutively expressed. Rather, its expression is 
triggered as part of immune response, hence the term inducible. As well, the iNOS control 
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mechanism is at the gene level owing primarily to its tight and calcium-independent interaction 
with CaM. During microbial infections, proinflammatory cytokines such as tumour necrosis 
factors (TNF) and interferons (IFN) bind the iNOS gene promoter in macrophage cells and trigger 
iNOS transcription.(Green et al., 1994) TNFs and IFNs are regulated by a positive feedback loop, 
causing a dramatic increase in iNOS expression during immune response. Macrophages and other 
phagocytic immune cells contain a considerable amount of reactive oxygen species (ROS) to aid 
in processing and clearance of infections. Since NO is a radical, it could react with ROS to form 
RNS such as peroxynitrite (ONOO-) and nitrogen dioxide (NO2).(Alderton et al., 2001) Both ROS 
and RNS induce damage to microbes which causes apoptotic cell death. Immune cells employ a 
cytoprotective system against ROS and RNS because they also pose danger to host cells in the 
same manner.(Joubert & Malan, 2011; Okamoto et al., 2010) Recall that NO activation of soluble 
GC increases intracellular cGMP levels. RNS react with cGMP to form the nitrated nucleotide 8-
nitro-cGMP, which then induce heme oxygenase (HO)-1. HO-1 has been shown to reduce host 
cell apoptosis.(Okamoto et al., 2010) In the event of NO overproduction by iNOS under normal 
physiological conditions, the HO-1-mediated cytoprotective mechanism gets overwhelmed and 
unnecessary cell death occurs and the increased activity of the immune system leads to symptoms 
akin to auto-immune diseases, including uncontrolled inflammation.(Okamoto et al., 2010) 
1.2.2 NOS structure and NO synthesis 
All NOS isozymes contain the same major domains: an N-terminal oxygenase domain and 
a C-terminal reductase domain that are connected by a CaM binding site.(Alderton et al., 2001; 
Stuehr, Santolini, Wang, Wei, & Adak, 2004) Figure 1.1a shows the crystal structure of the iNOS 
holoenzyme. The major domains are conserved across isozymes, consistent with the 50-57% 
sequence identity among them (Figure 1.1b). Additionally, NOS isozymes have similar quaternary 
shape, cofactor orientation and active site conformation. The reductase domain contains sites for 
the binding of cofactors flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and 
reduced nicotinamide adenine dinucleotide phosphate (NADPH), whereas the oxygenase domain 
has binding sites for (6R)-5,6,7,8-tetrahydrobiopterin (H4B), heme propionate and L-
arginine.(Alderton et al., 2001; Stuehr et al., 2004) NOS requires both dimerization and binding 
of the aforementioned cofactors for enzymatic activity to proceed.(Alderton et al., 2001; Stuehr et 
al., 2004) Both domains are catalytically active, allowing for biophysical studies to elucidate the 
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Figure 1.1. NOS holoenzyme structure. (a) Crystal structure of the published segments of the human 
iNOS. Note that the domain structures are obtained separately due to the highly dynamic nature of NOS. 
This image is a composite of the oxygenase (red, PDB ID: 1NSI) and the reductase (blue, PDB ID: 
3HR4) structures aligned using Chimera. These domains are linked by the CaM binding region (green). 
At the time of writing, there is no complete NOS holoenzyme structure available. (b) NOS isoform 
sequences are highly conserved; they contain the same domains and subdomains. 
Active NOS enzymes exist as homodimers; dimerization is required for function and 
binding of other cofactors. Once the dimer is formed, dissociating NOS into monomers requires a 
huge amount of energy (Mukherjee et al., 2014). As such, the NOS dimer is unlikely to separate 
unless subjected to heat or a denaturing agent. The importance of dimerization is highlighted by 
the fact that the amino acid residues involved in dimerization are highly conserved across 
isozymes. Each NOS subunit requires one molecule of H4B; H4B binds NOS at the dimer interface. 
It interacts with one NOS monomer via a conserved Trp residue through π-π stacking. H4B forms 





side chain.(Tejero & Stuehr, 2013) For the other NOS monomer, it coordinates water in an H-bond 
network with conserved Trp and Phe in the oxygenase domain.(Tejero & Stuehr, 2013) Its position 
near the active site allows H4B to function as an electron donor and acceptor during the NOS 
catalytic cycle.(Lang, Santolini, & Couture, 2011) It is important to note that the chirality of H4B 
affects its affinity towards NOS. The naturally occurring R isomer binds NOS at 17 times higher 
affinity than the S isomer.(Gross, Stuehrt, Jaffet, & Griffitho, 1990) 
Roman et al.’s crystal structure of the truncated domain showed that the rat nNOS reductase 
dimerize in addition to the oxygenase domains. This was similarly observed in Volkmann et al.’s 
cryo-EM studies of the full-length eNOS holoenzyme.(Volkmann et al., 2014) In contrast, 
Campbell et al.’s cryo-EM images of the full-length human iNOS holoenzyme show that only the 
oxygenase domains dimerize.(Campbell, Smith, Potter, Carragher, & Marletta, 2014) For all three 
isoforms, CaM appears to stabilize the dimer formation via its interactions with both subunits in 
addition to the CaM binding sites. 
1.2.2.1 NOS activation by CaM 
In addition to dimerization, all NOS isoforms also require CaM binding to produce NO. 
The 25-residue sequence between the reductase and oxygenase domains of a NOS monomer is a 
conserved region, to which CaM binds.(Curtin, Kinsella, & Stephens, 2015) The CaM binding 
regions of mammalian NOS isoforms follow a 1-5-8-14 motif, where the first, fifth, eighth and 
fourteenth residues in the binding sequence interact non-covalently with the CaM protein. (Figure 
1.2)(Curtin et al., 2015) In cNOS, these residues are conserved as Phe, Ala, Val and Leu, whereas 
in iNOS, the first two residues are replaced with Leu and Val.(Curtin et al., 2015) Furthermore, 
the iNOS CaM binding sequence itself contains more hydrophobic residues than those of cNOS. 
This increase in hydrophobicity is linked to the increased affinity of CaM for iNOS compared to 
cNOS. Indeed, CaM binds iNOS regardless of intracellular calcium concentration so that iNOS 
always exists as a tetramer (one NOS dimer, with CaM bound to each monomer).(Alderton et al., 
2001) Meanwhile, CaM binding to cNOS requires calcium to form the active tetramer. Previous 
studies have shown that nNOS and eNOS require 200-300 nM Ca2+ to achieve half maximal NO 






nNOS  R R A I G F K K L A E A V K F S A K L M 731 – 750 
eNOS  T R K K T F K E V A N A V K I S A S L M 491 - 510 
iNOS  R R E I P L K L K V K A V L F A C M L M 510 - 529 
                           1        5     8            14 
Figure 1.2. CaM binding sequence. Human NOS isoforms contain a conserved 1-5-8-14 CaM binding 
motif.  
 
The mechanism of NOS activation by CaM is currently not fully understood. However, 
recent studies using fluorescence, cryo-EM, pulsed electron resonance and spectroscopic 
techniques have shown that CaM promotes the electron flow from the reductase domain to the 
oxygenase heme by facilitating the interactions between these two domains.(Campbell et al., 2014; 
Volkmann et al., 2014)  
1.2.2.2 Catalytic mechanism 
An invariant Glu residue in the L-arginine binding site was found in all isozymes across 
species. Two guanidino nitrogens of the L-arginine substrate form a hydrogen bond with the 
carboxylate moiety of the conserved Glu residue at the NOS active site, in addition to a hydrogen 
bond with the carbonyl of the conserved Trp.(Fan, Stuehr, & Rousseau, 2009; Mukherjee et al., 
2014; Stuehr et al., 2004) The L-arginine substrate interacts with the heme propionate through its 
third guanidino nitrogen.(Mukherjee et al., 2014; Stuehr et al., 2004) Additionally, the π electrons 
of the guanidino group have stacking interactions with the heme rings to further stabilize the 
ligand-enzyme interaction.(Li et al., 2014; Mukherjee et al., 2014) These interactions, and thus the 
catalytic conversion of L-arginine into L-citrulline and radical NO powered by coupled electron 





Figure 1.3. NOS active site. In human nNOS, L-arginine (purple) is anchored to the active site by 
conserved Gln, Tyr and Glu residues (white). It also interacts with the heme (orange) via H bonding and π 
stacking interactions. The interaction of the heme propionate and active site residue Trp with the cofactor 
H4B (green) promotes the correct orientation of the substrate for oxidation. This active site was obtained 
from the crystal structure of the human nNOS oxygenase domain on PDB (4D1N). This image was created 
using Chimera. 
The intradomain electron flow from NADPH to FAD to FMN in the reductase domain 
involves a complicated conformational change that culminates in the inter-subunit reduction of the 
heme Fe(III) by FMN. To understand the different steps of the interflavin electron flow, the NOS 
reductase can be further divided into two subdomains: the NADPH/FAD subdomain and the FMN 
subdomain. The FMN subdomain is separated from the rest of the reductase via a 23-25 residue 
hinge sequence. This hinge region is flexible and facilitates the movement of the FMN domain to 
deliver the flavin to the appropriate redox partner. 
Prior to NADPH binding, the NOS dimer adopts an “open” state, in which the 
NADPH/FAD subdomain and the FMN subdomain are in an extended conformation. A conserved 
Phe reside (Phe1395 in nNOS) rotates such that NADPH directly sits on top the bound FAD 
molecule(Campbell et al., 2014; Leferink, Hay, Rigby, & Scrutton, 2014) As shown in Figure 1.4, 
NADPH donates a hydride ion to FAD and the NADP+-FADH2 complex is formed.(Yamamoto, 
Kimura, Shiro, & Iyanagi, 2005) The rotation by Phe then causes the NOS dimer to be in a “closed” 









C-terminal tail of the nNOS reductase domain has been shown to form a salt bridge with the 
negatively charged 2’ phosphate group of NADPH.(Tiso et al., 2005) This electrostatic interaction 
orients NADPH in such a way that it interacts with both the C-terminal end of the reductase and 
the FMN binding site, stabilizing the “closed” state of the NOS dimer. In this conformation, 
FADH2 quickly transfers an electron to FMN, forming the reduced FMNH.(Yamamoto et al., 
2005) The electron flow through the reductase domain occurs relatively quickly compared to the 
inter-domain electron transfer from FMN to the heme. Indeed, this is the rate limiting step in the 
NO biosynthesis. As shown in Figure 1.4b, the FMN subdomain becomes “unburied” from the rest 
of the reductase domain and “swings” toward the oxygenase heme.(Campbell et al., 2014) This 





Figure 1.4. Electron transfer in the NOS from the reductase domain to the oxygenase domain. (a) 
Crystal structures of NOS domains showing the electrons flow from NADPH to FAD to FMN in the 
reductase domain of NOS. The heme iron of the adjacent monomer (shown in white) acts as the last electron 
acceptor and facilitates the catalytic conversion of L-arginine into L-citrulline and NO. Reprinted from 
Nitric Oxide 23 (1) Daff, S. “NO synthase: Structures and mechanisms,” 1-11, 2010, with permission from 
Elsevier. (b) Proposed model of CaM activation and electron transfer showing both NOS monomers. 
Reprinted from FEBS Journal 282 (16) Leferink, N. et al. “Towards the free energy landscape for catalysis 








Figure 1.5. NOS enzyme catalysis. (a) The catalytic conversion of L-arginine into L-citrulline and NO 
involves two monooxygenation steps. (b) Both steps involve coupled electron and proton transfers to 
and from the heme iron. 
The catalytic conversion of L-arginine into L-citrulline and NO that occurs at the 
oxygenase domain is a two-step reaction (Figure 1.5), fueled by tightly coupled redox reactions. 
In a comprehensive review, Santolini presented different scenarios for the proton and electron 
transfers for both catalytic steps.(Santolini, 2011) Results from Brunel et al.’s study provide 
evidence supporting the most commonly accepted pathway, shown in Figure 1.5b and discussed 
below.(Brunel et al., 2016) It is important to note, however, that the exact mechanism of proton 
and electron transfers (and their respective donors) remains a point of contention in NOS research. 
The first step of the reaction begins with the reduction of the heme Fe(III) into Fe(II); the 
FMN domain swings toward the heme to deliver an electron from the reductase domain. Following 
this, O2 binds the heme iron to form an unstable Fe(II)-O2. This complex is rapidly reduced into 








it is immediately reduced back into H4B by the reductase domain.(Ramasamy, Haque, & Gangoda, 
2016) Next, Fe(III)-OO2- accepts two protons; the first proton comes from the L-arginine substrate 
while the second is from the distal H2O molecule in the H-bond network with the substrate and the 
heme.(Brunel et al., 2016; Santolini, 2011) The resulting Fe(III)-OOH loses water via heterolytic 
cleavage and collapses into Fe(IV)=Oπ·+, referred to as Compound I. Compound I then 
hydroxylates L-arginine via radical rebound and form Nω-hydroxy-L-arginine (L-NOHA). 
The second monooxygenase reaction proceeds similarly as the first step up until the 
protonation due to the lack of a distal H2O molecule in an H-bonding network with the substrate. 
Additionally, H4B·+ was not immediately re-reduced. The oxidation of L-NOHA involves the 
formation of a tetrahedral intermediate that is covalently bound to Fe(III)-OOH. What follows is 
the formation of Fe(II)-N=O and L-citrulline, and the loss of a hydroxide ion. At this point, NO 
remains covalently linked to the heme. Its release requires the oxidation of Fe(II) into Fe(III) by 
H4B·+ from before.  
1.3 NOS regulation 
All NOS isoforms contain structures that facilitate internal regulation, i.e. without the aid 
of external cofactors. These regulatory factors are the C-terminal (CT) tail and the autoinhibitory 
(AI) loop. Both of these block heme reduction by interfering with CaM binding, thereby preventing 
heme reduction.  
The C-terminal (CT) tail, which is a sequence of 21 to 42 amino acids at the C-terminus of 
NOS.(Roman, Marta, Sue, Masters, & Domain, 2002) The CT tail is thought to inhibit the NOS 
reductase activity. In eNOS, the CT tail is subject to another layer of regulation, by way of post-
translational modification. Ser1179 in the CT tail is a conserved residue is phosphorylated upon 
shear stress stimuli due to a local increase in blood pressure.(Fleming & Busse, 2003) This 
phosphorylation allows eNOS to bind CaM at resting [Ca2+], which results in an increase in NO 
production to counter the increase in blood pressure. Studies with the phosphomimetic mutation 
Ser1179Asp showed that CaM binding and Ser1179 phosphorylation have equivalent effects on 
the rate of electron transfer, as evidenced by NADPH-dependent flavin reduction.(Haque, Ray, & 
Stuehr, 2016) Furthermore, Ser1179Asp has higher NO production than the wild type eNOS with 
and without CaM binding. As such, Ser phosphorylation appears to have an additive effect to CaM 
binding with regard to heme reduction. 
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The AI loop found between the FMN binding domain and the CaM binding 
region.(Weissman, Jones, Liu, & Gross, 2002) This AI loop locks the FMN in its electron 
accepting state, i.e. “buried” in the FAD/NADPH subdomain, at low [Ca2+]. In other words, the 
AI loop prevents the electron flow to the oxygenase heme when CaM is not bound to nNOS or 
eNOS. Relatedly, the removal of this AI loop in nNOS results in a decrease in Ca2+-dependence 
of NOS activity.(Montgomery, Romanov, & Guillemette, 2000) Furthermore, when the AI loop 
sequence was inserted into iNOS, there was a 1/3 decrease in NO production.(Weissman et al., 
2002) Such results imply that the AI loop interferes with CaM binding and its role on the electron 
flow. 
1.4 NOS inhibition 
As mentioned previously, the endogenous NO exists in tightly controlled levels during 
normal physiological state. Overproduction of NO leads to a wide array of pathologies. As such, 
the development of NOS inhibitors that are selective towards either nNOS or iNOS, which have 
been implicated in NO-related pathologies. Recall that eNOS activity is necessary for normal 
physiological processes and, hence, must not be inhibited. Indeed, most adverse effects associated 
with NOS inhibitors are cardiovascular-related and are due to off-target inhibition of eNOS. 
However, the high similarity among the isoforms (especially at the active site) presents a problem 
in designing selective inhibitors. Yang et al.’s recent review reports that more than 100 patents 
have been filed for NOS inhibitor compounds from 2011-2014 alone, in addition to the already 
existing parents from the discovery of the NOS enzymes.(Yang et al., 2014) Unfortunately, at the 
time of writing, none of the isoform-specific NOS inhibitors in development have been approved 
for clinical trials. Note, however, that some non-selective first generation inhibitors have been used 
as eNOS blockers to induce peripheral hypertension in clinical trials (Víteček, Lojek, Valacchi, & 
Kubala, 2012). 
1.4.1 Classes of NOS inhibitors 
NOS inhibitor compounds can be categorized according to their binding targets on the 
holoenzyme structure. Most of these compounds target the active site to directly compete with 
substrate binding and prevent catalysis. These mechanism-based inhibitors include L-arginine 
derivatives and compounds that contain moieties that mimic the guanidine group and ionisable 
amines of L-arginine. However, owing to the highly conserved active site, these compounds tend 
to be non-selective.  
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 Non-mechanism based inhibitors are also being developed. These compounds target the 
binding sites for cofactors H4B, CaM and NADPH.(Curtin et al., 2015; Mukherjee et al., 2014) 
Heme-Fe blockers, which disrupt the metal-poryphyrin coordination at the active site, are also 
being developed.(Mukherjee et al., 2014) Furthermore, NOS dimerization blockers have been 
investigated because NOS monomers are inactive.(Mukherjee et al., 2014) However, these binding 
targets contain motifs for H4B, CaM and NADPH that also occur in other proteins. As such, off-
target inhibition may occur, which can lead to adverse effects. For instance, the cofactor CaM is 
known to bind and activate over 300 different proteins, some of which contain the 1-5-8-14 binding 
motif. One such protein is troponin C in cardiac and smooth muscle cells. Blocking CaM binding 
to these proteins could lead to serious cardiovascular effects. As a result, the majority of NOS 
inhibitors in development target the active site of the enzyme. 
1.4.2 Approaches in isoform-selective inhibitor design 
The problem of NOS selectivity arises from the fact that currently targeted binding sites 
are highly conserved across all three isozymes, particularly the catalytic active site that contains 
an invariant Glu residue. Despite some variation in the amino acid sequence, crystal structure 
alignments of the NOS isozymes suggest that the overall molecular shapes of these enzymes are 
nearly identical (Figure 1.6). This identity in domains is consistent with the fact that all NOS 





Figure 1.6. Human NOS oxygenase structures are highly conserved across isoforms. (a) Aligned 
crystal structures of the human NOS oxygenase doimain show highly conserved domain structures of NOS 
isozymes. (b) NOS isoforms exhibit single residue differences in the active site and vicinal structures. 
Human nNOS (cyan; PDB: 4D1N), human eNOS (magenta; PDB: 4D1O) and human iNOS (yellow; PDB: 
1NSI) oxygenase domains aligned using Chimera. 
In their patent review, Yang et al. (2014) listed the major classes of core structures for 
isoform-selective NOS inhibitors. Selective NOS inhibitors are generally based on pyrrolidine, 
quinoline, indole, pyrazole and aminopyridines.(Yang et al., 2014) These inhibitor cores are all 
cyclic and contain ionisable amines that can be H-bond donors or acceptors; all except pyrrolidine 
are also aromatic (Figure 1.7). Over the years, the design of selective NOS inhibitors progressed 
towards bulkier compounds that contain guanidino and amino moieties, and more extended 
conformation with hydrophobic and hydrogen bonding sites.(Joubert & Malan, 2011) Guanidino 
and amino moieties contain ionisable amines which mimic L-arginine binding to position and 











(2014) report that inhibitor design follow different trends depending on the targeted NOS isoform. 
For example, the Poulos and Silverman groups from University of California Irvine and 
Northwestern University, respectively, have independently and jointly developed double-headed 
symmetric and asymmetric compounds that appear to be selective towards nNOS. The compound 
“heads” are rings, usually pyrrolidine or quinolone, which interact with the heme and side chains 
conserved aromatic residues. Meanwhile, iNOS selective inhibitors, such as those developed by 
the pharmaceutical company Kalypsys, are pyrimidine derivatives with heteroalkyl moieties. In 
any case, the extended conformations of these bulky compounds are designed to target remote 
isoform specific binding sites, which increase inhibitor selectivity.(Garcin et al., 2008; Joubert & 
Malan, 2011) Combining these two properties, Garcin et al.’s anchored plasticity approach in drug 




Figure 1.7. Chemical structures of major NOS inhibitor cores and examples of novel selective 
inhibitors. (a) From Yang et al.’s (2014) patent review, selective NOS inhibitors are based on 
pyrrolidine, quinoline, indole, aminopyridine and pyrazole. (b) Garcin et al.’s (2008) Novel iNOS 
selective inhibitor based on bicyclic thienooxapenzine from (left) and Cinelli et al.’s (2015) novel nNOS 

















In anchored plasticity, an inhibitor core is “anchored” at the conserved active site.(Garcin 
et al., 2008) An inhibitor tail is extended to sites just outside the binding pocket and access residues 
that can form new sites for inhibitor-binding. Garcin et al. identified first-, second- and third-shell 
amino acids that change conformation upon ligand-binding at the NOS active site. These so-called 
“plastic residues” change side chain conformation when the inhibitor binds at the active 
site.(Garcin et al., 2008) Some of these residues outside the active site vary across isoforms; after 
all, they do not directly participate in NOS catalysis and, hence, are less likely to be conserved. 
Novel selective NOS inhibitors could then be designed to take advantage of these isoform-specific 
plastic residues in the second and third shells (Figure 1.8). 
 
Figure 1.8. Anchored plasticity. Plastic residues in the vicinity of the conserved active site can be used 
as targets for isoform selective inhibition. Reprinted from the supplementary material of Nat. Chem. Biol. 
(4) Garcin, E. D. et al. “Anchored plasticity opens doors for selective inhibitor design in nitric oxide 
synthase.” 700–707, 2008, with permission from Nature Publishing Group. 
Using this approach, Garcin et al. discovered a Gln specificity pocket in human and murine 
iNOS which is an extended pocket next to the heme pocket, composed of the first shell Gln, Tyr 
and Arg residues.(Garcin et al., 2008) This pocket forms when a bulky inhibitor, i.e. ones with 
rigid and extended tails, forces the first shell Gln residue to rotate away from its neighbouring Tyr 
residue; this rotation then causes the formation of a new H-bond with another Arg residue, also in 
the first shell.(Garcin et al., 2008) The Arg side chain rotates towards and pushes away the second 
shell Asn.(Garcin et al., 2008) Note that the inhibitor tail must be hydrophobic so that hydrophobic 
interactions with the specificity pocket stabilizes the complex. Binding of the same inhibitor to 
eNOS does not cause the formation of this Gln pocket because the third shell residues of eNOS, 
Leu and Ile, prevents the movement of the second shell Asn; specificity pocket formation was 
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observed in the eNOS mutant with the third shell residues of iNOS, Phe and Val.(Garcin et al., 
2008) The Gln specificity pocket allowed Garcin et al. to design a series of novel human and 
murine iNOS inhibitors with 125- to 3000-fold selectivity over bovine eNOS.(Garcin et al., 2008) 
Using similar concepts, Cinelli et al. reported a series of aminoquinoline-derived nNOS 
selective inhibitors.(Cinelli et al., 2015) These compounds contain ionizable amines that H-bonds 
with the invariant active site Glu and extended tails that are long enough to access a hydrophobic 
pocket proximal to the heme and the H4B binding sites.(Cinelli et al., 2015) These compounds also 
have central aromatic rings that have π-stacking interactions with the nNOS active site Tyr.(Cinelli 
et al., 2015) Further, inhibitor binding at the nNOS active site induces the formation of a 
hydrophobic pocket with residues Tyr, Leu and Met, which does not occur in eNOS due to the 
difference in Tyr conformation between nNOS and eNOS.(Cinelli et al., 2015) In eNOS, the Tyr 
phenyl ring is perpendicular to the plane of the heme, so steric interactions prevent rotation of the 
Tyr side chain that would cause the formation of the hydrophobic pocket.(Cinelli et al., 2015)  
1.4.3  Human and non-human NOS isoforms 
Human NOS holoenzymes are difficult to isolate due to their instability. As well, the 
expression and purification of these human cNOS are, as of yet, quantitatively inferior to that of 
the rat nNOS and bovine eNOS. These non-human cNOS have well-established expression 
systems that provide yields quantitatively superior to their human counterparts.(Huang et al., 2012) 
Non-human NOS have a high sequence similarity with human NOS (96%, 95% and 87% for 
nNOS, eNOS and iNOS, respectively) and as such, they have been used extensively as model 
systems for inhibitor design.  
Until recently, the eNOS and iNOS oxygenase domain was the only available crystal 
structure for human NOS (Fischmann et al., 1999). The crystal structures of the human nNOS and 
eNOS have only been published in 2014 (Li et al., 2014). Furthermore, there are no published 
crystal structures for the full-length NOS, owing to the highly dynamic nature of the holoenzymes. 
Relatedly, drug development research (both experimental and theoretical) relied on the crystal 
structures of the rat nNOS and bovine eNOS oxygenase domains, instead of the human cNOS. 
However, structure alignments of the human and non-human NOS oxygenase domains reveal that 
the minute differences in the amino acid sequence correspond to differences in structure (Figure 
1.9 Figure 1.10). Li et al. report that while human cNOS exhibit the similar helix structures and 
disordered loops, the active sites of the human isoforms show minute disparities.(Li et al., 2014) 
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Specifically, there are single amino acid differences in the active and its vicinity, which tend to 
form isoform-specific hydrophobic pockets. Hence, these structural differences result in 
differences in the kinetics of enzyme catalysis. The Michaelis constants Km for the NOS substrate 
L-arginine have been shown to vary between human and non-human NOS. Other kinetic 
parameters, such as Vmax and specific activity, also vary. These discrepancies affect the selectivity 
of NOS inhibitors; novel inhibitor-enzyme bonding interactions may occur and alter affinity and 
selectivity.(Boer et al., 2000; Cinelli et al., 2014) Cinelli et al. directly compared the inhibitory 
activity of the selective nNOS inibitors that they have synthesized on rat and human nNOS; their 
results show a consistently higher Ki values, i.e. lower potency, in human nNOS than in rat nNOS.( 
Cinelli et al., 2015; Cinelli et al., 2014) The decreased affinity may be a consequence of designing 
the compounds using non-human NOS enzymes, specifically because the single residue difference 
of Leu (rat) to His (human) at the hydrophobic pocket near the active site that forms upon inhibitor 
binding.(Cinelli et al., 2015; Cinelli et al., 2014)  
 
 
Figure 1.9. Sequence alignment of active site residues of human and non-human cNOS. Residues 





Figure 1.10. Alignment of human and non-human NOS oxygenase domains. (a) nNOS, (b) eNOS and (c) 
iNOS. The darker colours represent the human NOS and lighter colours refer to non-human NOS. The 
structural differences between human and non-human NOS are evident in the disordered loop sections, as 
highlighted. These structures are aligned using Chimera. 
 
1.4.4 Inhibitors used in this study 
 This project presents a systematic approach on studying the differences in inhibition 
kinetics between human and non-human NOS. Preliminary experiments are performed using first 
generation active site inhibitors. These include non-selective inhibitors NG-monomethyl-L-
arginine (L-NMMA), NG-nitro-L-arginine (L-NNA) and Nω-allyl-L-arginine (L-ALA), all of 
which are L-arginine derivatives. Bulky compounds 3-bromo-7-nitroindazole and 1400W (N-(3-






nNOS and iNOS, respectively. In addition to active site inhibitors, CaM binding inhibitors 
trifluoroperazine (TFP) and melatonin are also examined. 
1.5 Purpose of study 
Despite the high homology with their human counterparts, conclusions drawn from studies 
of the non-human NOS may not be reasonably translatable to humans, given the small differences 
that might lead to isoform-specificity. As previously mentioned, the slight differences in structure 
may be the cause of kinetic differences in the activity of human and non-human NOS. Hence, it is 
important to determine these differences using a uniform study. As Curtin et al. recently pointed 
out, there is not yet a consistent human NOS isozyme assay system for studying the inhibitory 
activity of NOS inhibitors.(Curtin et al., 2015) BRENDA (The Comprehensive Enzyme 
Information System; formerly, Braunschweig Enzyme Database) lists an array of Km values for L-
arginine for different NOS isoforms, as well as Ki and IC50s. These values were acquired via 
different methods: either directly through radiolabeled L-arginine or indirectly via the Griess 
reaction or the oxyhemoglobin capture assay. Furthermore, the NOS protein sources were not 
uniform either. Some were purified heterologously expressed proteins, while some were isolated 
from tissue extracts. Others even utilized crude lysates. Without the uniformity in activity assay 
methods, the inhibitors cannot be compared directly. As such, the main objectives of this master’s 
thesis are to: 
1. Develop heterologous human NOS holoenzyme expression systems with comparable 
quantitative and qualitative yields to established non-human NOS expression systems 
2. Assess the NOS inhibition kinetics of first generation active site inhibitors and CaM-





2. Enzymatic activity of human and non-human NOS holoenzymes 
2.1 Introduction 
 Although the gene sequences of the human constitutive NOS isozymes have been isolated 
and cloned since the mid-90s, the structure-based design of NOS inhibitors still relies on non-
human NOS models. Non-human NOS expression systems, such as rat nNOS and bovine eNOS, 
have well-established growth and purification methods that give high protein yields. In contrast, 
current human NOS expression systems yield less proteins than their non-human counterparts. 
This chapter describes the development of optimal expression systems for human constitutive NOS 
enzymes.  
2.1.1 Vector selection 
 The choice of plasmid vector dictates the efficiency of heterologous protein expression. To 
optimize the expression of NOS, two vectors are considered: pCWori and PDS-78. Both vectors 
utilize IPTG induction to effect protein synthesis. 
 pCWori (4955 bp) contains the tac promoter, which is a hybrid of the trp and lacUV5 
promoters. The tac promoter is a favourable binding site for the E. coli RNA polymerase, which 
is readily expressed by most E. coli strains. The E. coli RNA polymerase binds the tac promoter 
and initiate gene transcription upon the addition of IPTG. IPTG de-represses the tac promoter by 
allosterically modifying the lac repressor that constitutively inhibits the binding of RNA 
polymerases to the promoter region. pCWori is a commonly used vector for the heterologous 
expression of oxidoreductases such as NOS and cytochrome P450 (Roman et al., 1995). 
 Meanwhile, PDS-78 (5488 bp) is a high-expression derived from pET28a. This vector 
contains a T7 promoter region, which binds the T7 RNA polymerase. The T7 RNA polymerase is 
a highly efficient polymerase that is not normally expressed in E. coli. Once T7 RNA polymerase 
is synthesized upon induction by IPTG, it binds the T7 promoter and effect the transcription of the 
protein of interest. Heterologous proteins tend to be over-expressed because the T7 RNA 
polymerase is highly efficient, especially compared with the native E. coli polymerase. 
 The full-sequence human nNOS and eNOS holoenzymes have been cloned into PDS-78 
(pHnNOShisKan and pHeNOShisKan, respectively), but have not yet been purified using 
established protocols in the lab. 
2.1.2 E. coli strain 
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 Heterologous protein expression may be hindered by codon usage incompatibility between 
the host organism and the gene donor. Although the genetic code is redundant, some species favour 
specific codons over others. For example, E. coli exhibit codon usage bias. E. coli does not produce 
tRNA that correspond to codons that rarely appear in its genome. In contrast, the human genome 
does not exhibit such bias. Hence, codons that do not appear in the E. coli genome may be in the 
transplanted human gene. Genes that contain rare E. coli codons have been reported to have 
reduced synthesis rates, and contain frameshift mutations and mistranslations. Codon usage bias 
could also negatively affect protein folding.  
 In this project, both the human nNOS and eNOS holoenzyme genes each contain more than 
10 instances of the Arg rare codons AGA, AGG and CGA. Thus, the E. coli strain BL21 (DE3) 
may be unsuitable for human nNOS and eNOS expression. The modified strain BL21 (DE3) 
CodonPlus RP could suffice, since its phenotype includes tRNA for rare codons AGA, AGG and 
CGA (Arg) and CCC (Pro). 
2.1.3 Chaperone proteins 
 High concentrations of heterologous protein in bacterial cells are susceptible to aggregation 
due to protein misfolding. Aggregation presents challenges to protein purification, especially in 
chromatographic techniques. For gel filtration, the formation of inclusion bodies changes the 
elution time of the protein. Additionally, aggregation prevents the adsorption of the protein via 
specific binding sites if these sites are buried into the core of the aggregate. These problems can 
be overcome by the co-expression of chaperone proteins such as Gro-ES and Gro-EL. Gro-ES and 
Gro-EL encapsulate a protein and help it refold into its native state, and thus reducing its 
aggregation propensity. 
2.1.4 Use of truncated NOS holoenzymes 
 Removing the first several amino acids of human NOS holoenzymes have been shown to 
improve yields from heterologous expression systems. Truncated NOS are less prone to 
proteolysis. Indeed, the human iNOS expression system used by the Guillemette group lacks the 
first 70 amino acids at the N-terminal. The yields in this expression system are comparable to the 
long established rat nNOS and bovine eNOS expression systems. In this project, 290 N-terminal 
amino acids of the human nNOS are removed; the human eNOS lacks the first 66 amino acids. 
 This truncation may be especially important with regard to the nNOS isoform. Recall that 
the nNOS holoenzyme contains an additional PDZ domain that is absent in both the eNOS and 
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iNOS. The PDZ domain is 220 amino acid long and thus, presents more sequences that can be 
targeted by proteases. Furthermore, the PDZ domain acts as an anchoring domain, which may 
promote troublesome protein-protein interactions that can lead to aggregation. If so, then the 
inclusion of this domain could decrease not only the protein yield, but also the catalytic activity of 
the enzyme.  
2.2 Methods 
2.2.1 Subcloning human NOS holoenzymes into pCWori  
 The pCWori vector is not commercially available, so the linearized vector is obtained from 
pBeNOShisAmp, which is a plasmid that was constructed by the Guillemette group. Polymerase 
chain reaction (PCR) was used to truncate and amplify the full NOS sequences. Both the forward 
and reverse primers contain 5’. These restriction sites allow for insertion into the desired vector 
via ligation. 
 Successful constructs were verified via analytical restriction digests and nucleotide 
sequencing. The Guillemette group avails sequencing services from The Centre for Applied 
Genomics Sanger Sequencing Facility in Toronto, ON. 
2.2.1.1 Competent E. coli cell transformation 
 In this project, two cell transformation methods were employed: electroporation and CaCl2 
heat shock. Both methods require aseptic conditions. In electroporation, electrocompetent cells 
were transformed by adding 0.3 µL of plasmid DNA sample into 40 µL of cell stock. The cell and 
DNA mixture was transferred into 0.1-cm gap electroporation cuvettes (Bio-Rad), and pulsed with 
approximately 1800 V for about 5 ms. The pulsed cells were then suspended in 500 µL non-
selective Luria-Bertani (LB) broth and incubated at 37 ˚C for 1 hour at 250 rpm. 100 µL of the cell 
suspension was spread-plated onto a selective LB-agar plate. The plates were stored in a 37 ˚C 
incubator for 16 hours, after which they were checked for visible colonies.  
 For the CaCl2 heat shock method, 5 µL of the plasmid DNA sample was added into 100 
µL of chemically competent cells in a microfuge tube. The cell and DNA mixtures were incubated 
on ice for 30 minutes. These were then heat shocked via a 2-minute water bath at 42 ˚C, which 
was immediately followed by a 2-minute incubation on ice. Afterwards, 100 µL of LB broth was 
added into the mixture and the tubes were incubated in a 37 ˚C water bath for 1 hour without 
shaking. 100 µL of the cell suspension was plated onto a selective LB-agar plate, as above. The 
plates were stored in a 4 ˚C refrigerator when not in use. 
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2.2.1.2 Plasmid DNA sample preparation 
 To obtain DNA plasmid samples, competent E. coli DH5α cells were transformed and 
plated onto selective LB-agar media. Distinct colonies were used to inoculate 2 mL terrific broth 
(TB) with the appropriate antibiotics and grown for 16 hours at 225 rpm at 37 ˚C. Plasmid DNA 
were extracted using silica resin spin columns according to manufacturer instructions (BioBasic). 
DNA were eluted with and stored in 2 mM Tris buffer (pH 8.0-8.5) and concentrations were 
determined using the NanoDrop 2000 (ThermoScientific). Samples were stored in –20 ˚C. 
2.2.1.3 pCWori vector preparation 
 The pCWori vector in pBeNOShisAmp contains the ATG start codon and a poly-histidine 
tag in its 3’ end, upstream of an NdeI restriction site. Meanwhile, the 5’ end contains an EcoRI 
recognition sequence. Hence, pBeNOShisAmp was digested with both NdeI and EcoRI (Thermo 
Fisher) to isolate the 4955-bp fragment. To maximize the fragment yields, the enzymatic reactions 
were scaled up, such that approximately 5 µg of plasmid DNA was digested in each reaction tube. 
The reaction was allowed to progress through incubation at 37 ˚C for 1 hour and then stopped via 
heat inactivation at 65 ˚C. Agarose gel electrophoresis was used to separate the fragments 
according to size (See Section 2.2.1.5 for more details). 
2.2.1.4 PCR amplification of gene inserts 
 As mentioned previously, the constitutive NOS genes were truncated at the N-termini to 
improve protein yields. Hence, the forward primers for each the nNOS and eNOS were designed 
such that the NdeI restriction site was followed by the codons for 291st and 67th amino acids, 
respectively. These primers are complementary to eight codons on the original template. Note that 
the ATG start codon is already in the vector fragment, so it was not added. The reverse primers 
were the complementary sequence to the final nine codons, including the stop codon, plus the 









Table 2.1. Forward and reverse primers (FP and RP) for PCR amplification of truncated human nNOS 
and eNOS with GC content and melting temperatures (Tm). Highlighted sequences correspond to the 
restriction sites for NcoI (cyan), NdeI (yellow) and EcoRI (green). 
Primer Sequence GC Tma 
hnNOSΔ290FP 5’ CCACCATGGTCATATGGGAAAACAGTCCCCCACAAAGAATGGC 3' 51.2% 75.9 ˚C 
hnNOSholoRP 5’ GCGGAATTCTTAGGAGCTGAAAACCTCATCGGTGTC 3’ 50.0% 72.8 ˚C 
heNOSΔ66FP 5’ CCACCATGGTCATATGCCCAAGTTCCCTCGTGTGAAGAACTGG 3’ 53.5% 76.1 ˚C 
heNOSholoRP 5’ GCGGAATTCTCAGGGGCTGTTGGTGTCTGAGCCGGG 3’ 63.9% 77.7 ˚C 
a Tm values were calculated with the primer concentration at 0.5 µM, [NaCl] at 0 mM, [MgCl2] at 2 mM and 
[dNTPs] at 200 µM using the IDT OligoAnalyzer®. 
 
 PCR amplification of the truncated human nNOS and eNOS sequences were performed 
using the pHnNOShisKan and pHeNOShisKan as templates, respectively. The reactions were 
performed using high-fidelity polymerase Phusion® (Thermo Fisher). In addition to 0.02 U/µL 
Phusion® enzyme and the provided high-fidelity buffer, each 50 µL reaction mixture contained 
about 10 ng of template DNA, 0.5 µM of forward primer, 0.5 µM of reverse primer, 200 µM dNTP 
mixture and 2 mM MgCl2. Since the Tm values are above the optimal extension temperature of the 
Phusion® polymerase, a two-step PCR program was utilized: 
Table 2.2. Two-step PCR program for amplification of truncated human nNOS and eNOS sequences. 
PCR Step Temperature Duration, mm:ss Cycles 
Initial Denaturation 98 ˚C 05:00 1 
Denaturation 98 ˚C 00:10 
35 
Annealing/Extension 72 ˚C 06:00 
Final Extension 72 ˚C 10:00 1 
Hold 4 ˚C Indefinite - 
 
Ligation into the pCWori vector requires the generation of complementary 5’ sticky ends 
for the inserts. The PCR products were digested with EcoRI and NdeI directly without purification: 
2 µL of the FastDigest Green Buffer, 1 µL of EcoRI and NdeI each, and 16 µL of MQW were 
added into 10 µL of the PCR mixture. This 30 µL reaction mixture was incubated in a 37 ˚C water 
bath for 1 hour. The reaction was stopped by heat inactivation at 65 ˚C for 15 minutes. The human 
nNOSΔ290 sequence was expected to be 3441 bases long, while the human eNOSΔ66 should have 
3417 bases. The digested insert sequences were separated from non-specifically amplified 
fragments via agarose gel electrophoresis (see Section 2.2.1.5). 
2.2.1.5 DNA fragment isolation 
 Once the vector and insert fragments were digested with the appropriate restriction 
enzymes, the fragments of interests were separated by electrophoresis using 1% agarose gel in pH 
8.3 TBE buffer (89 mM Tris-borate, 89 mM boric acid, 2 mM ethylenediaminetetraacetic 
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[EDTA]). The agarose gels were cast with large wells (approximately 5 cm by 1 mm) to allow for 
loading large volumes of restriction digest mixtures. The DNA fragments were visualized under 
ultraviolet (UV) light using ethidium bromide (EtBr). 
 Sections of the agarose gel containing the fragments of interest were excised using a clean 
blade and transferred into 1.5 mL microfuge tubes. The DNA fragments were extracted using silica 
resin spin columns per manufacturer instructions (BioBasic). The DNA concentrations were 
estimated using NanoDrop 2000, and the fragment lengths were verified by agarose gel 
electrophoresis. Samples, which were eluted with 2 mM Tris buffer (pH 8.0-8.5), were stored in –
20 ˚C. 
2.2.1.6 Ligation into pCWori 
 The nNOS and eNOS inserts were subcloned into the linearized pCWori vector via ligation 
using the T4 DNA ligase (Thermo Fisher). The ligation reactions were performed at 20 µL 
volumes, each containing 50 ng of pCWori, 1 U of T4 DNA ligase, excess ATP (at least 2.5 mM) 
and MQW. The amount of insert sequence added into the reaction was varied from 1:1 to 3:1 molar 
ratio over the vector.  
The ligation reactions were incubated at 16 ̊ C for either 1 hour or 16 hours. For both cases, 
the reactions were stopped via heat inactivation at 65 ˚C for 5 minutes. The ligation mixtures were 
used to transform competent DH5α cells (see Section 2.2.1.1) directly without purification. Visible 
colonies were used to inoculate TB media for plasmid DNA preparation (see Section 2.2.1.2). 
Successful constructs are heretofore referred to as pHnNOSΔ290hisAmp and 
pHeNOSΔ66hisAmp.  
2.2.1.7 PCR-based site directed mutagenesis 
 PCR was used to reverse spontaneous mutations that arose during the amplification 
process. Sequencing information show that the human nNOSΔ290 holoenzyme amplicon 
(pHeNOShisKan) was found to have three spontaneous mutations, only one of which occurs 
naturally and is considered benign.(C. (Erica) Lee, 2015) One mutation, a G to A base change, 
caused Gly to become Arg. Because this amino acid is within the NADPH-binding site of the 
human nNOS reductase domain, this mutation may have negative effects in expression and activity 




 Two completely complementary primers were designed based on standard site-directed 
mutagenesis protocols. In addition to the target nucleotide (A to G), an additional control mutation 
was introduced such that the success of the mutagenesis can be verified without sequencing. This 
control came in the form of a silent mutation (C to G; ACC and ACG both code for Thr) that 
removes the NcoI recognition site (5’ CCATGG 3’) near the target nucleotide.  
Table 2.3. Forward and reverse primers (FP and RP) for PCR-based site-directed mutagenesis of human 
nNOSΔ290 holoenzyme (pHnNOSΔ290hisAmp)with GC content and melting temperatures (Tm). 
Highlighted sequences correspond to the NcoI restriction site prior to the mutation. Bolded letters refer to 
the target mutations. 
Primer Sequence GC Tma 
NADPH FP 5’ CACATATACGTCTGTGGGGACGTCACGATGGCTGCTGATGTCC 3' 55.8% 76.3 ˚C 
NADPH RP 5’ GGACATCAGCAGCCATCGTGACGTCCCCACAGACGTATATGTG 3’ 55.8% 76.3 ˚C 
a Tm values were calculated with the primer concentration at 0.5 µM, [NaCl] at 0 mM, [MgCl2] at 2 mM and 
[dNTPs] at 200 µM using the IDT OligoAnalyzer®. 
 
 Completely complementary primers, especially ones as long and as GC-rich as NADPH 
FP and NADPH RP, present problems that could hinder PCR amplification and thus, the 
mutagenesis. To expedite the process, touchdown (TD) PCR experiments were performed using 
multiple combinations of reaction components. The amount of template used was varied from 10 
to 100 ng, and the effect of primer concentration (0.5 µM versus 2.5 µM) was tested. Mg2+ content 
was investigated by varying MgCl2 concentrations from 1.5 to 2.5 mM. Dimethyl sulfoxide 
(DMSO) was added to 3% and 5% to assess its effects on amplification. In some attempts, 
AccuTaq™ DNA polymerase (Sigma) was also used in lieu of Phusion®. All PCR experiments 
were performed in 50 µL volumes. 
Table 2.4. Touchdown PCR program for site-directed mutagenesis of pHnNOSΔ290hisAmp. 
PCR Step Temperature Duration, mm:ss Cycles 
Initial Denaturation 98 ˚C 03:00 1 
Denaturation 98 ˚C 00:30 
2b Annealing 72 – 55.5 ˚Ca 01:00 
Extension 72 ˚C 10:00 
Denaturation 98 ˚C 00:30 
18 Annealing 68 ˚C  01:00 
Extension 72 ˚C 10:00 
Final Extension 72 ˚C 10:00 1 
Hold 4 ˚C Indefinite - 
a The annealing temperature was decreased from 72 to 55.5 ˚C in 1.5 ˚C increments. 
b Two PCR cycles per annealing temperature. 
 
 Furthermore, parallel single-primer PCR experiments (with varying template and DMSO 
concentrations using the TD-PCR protocol) were performed to discourage primer-dimer 
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formation. In this case, only one primer (NADPH FP or NADPH RP) is added into the PCR 
mixture, which are combined after the amplification process and the DpnI digest. The single 
stranded complementary DNA were denatured at 98 ˚C and allowed to anneal completely by slow 
cooling to 37 ˚C. The combined forward- and reverse-primer PCR reactions were then used to 
transform competent DH5α cells, as described above. 
 Plasmid DNA were extracted from visible colonies and were subject to analytical digests 
with NcoI, EcoRI and NdeI. Potential mutants were sequenced to further confirm successful 
mutagenesis, as well as to check for spontaneous mutations.  
2.2.2 Growth and expression of NOS holoenzymes 
 The transformation process for the expression of human and mammalian NOS proteins was 
similar to the procedures described in Section 2.2.1.1. However, the E. coli strain used was either 
BL21 (DE3) or BL21 (DE3) CodonPlus RP, instead of DH5α. The mammalian NOS (rat nNOS, 
bovine eNOS and murine iNOS) and the human iNOS holoenzymes have well-established 
expression systems that utilize the BL21 (DE3) strain. The rat nNOS (pRnNOShisAmp) and 
bovine eNOS (pBeNOShisAmp) were each co-expressed with GroES/EL proteins 
(pGroESLChlor) in BL21 (DE3). Meanwhile, the mouse iNOS (pMiNOSAmp) and the human 
iNOS (pHiNOSΔ70hisAmp) were both co-expressed with wild-type calmodulin (pCaMChlor), 
also in BL21 (DE3). 
 To assess the compatibility of E. coli strains in heterologous NOS expression, human 
nNOS and eNOS holoenzymes (pHnNOSΔ290hisAmp and pHeNOSΔ66hisAmp, respectively) 
were expressed in both BL21 (DE3) and BL21 (DE3) CodonPlus RP. In the former, co-expression 
with GroES/EL was possible because this strain does not have innate chloramphenicol resistance. 
In contrast, the latter contains tetracycline and chloramphenicol resistance such that expression for 
the GroES/EL plasmid cannot be selected for using antibiotic pressure. The high-expression 
plasmids pHnNOShisKan and pHeNOShisKan were also expressed in a similar manner. 
2.2.2.1 Small-scale growth for verification of expression 
 To confirm that pHnNOShisKan, pHeNOShisKan, pHnNOSΔ290hisAmp and 
pHeNOSΔ66hisAmp would be expressed upon induction with isopropyl β-D-1-
thiogalactopyranoside (IPTG), small-scale growth experiments were performed. 2 mL of TB with 
appropriate antibiotics was inoculated with a single colony of human nNOS- or human eNOS-
expressing BL21 (DE3) or BL21 (DE3) CodonPlus RP. (Where possible, these NOS holoenzymes 
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were co-expressed with pGroESLChlor.) These cultures were left to grow for 16 hours at 37 ˚C at 
250 rpm. Then, 1 mL of these starter cultures were used to inoculate 100 mL of TB with antibiotics. 
The OD600 of the media were monitored regularly until it reaches 1.0–1.2, at which point 500 µM 
IPTG was added to induce protein expression. The incubation temperature was decreased to 25 ˚C 
upon induction. 
 Culture samples (1 mL) were collected right before and 40 hours after induction. The OD600 
of these samples recorded. Samples were centrifuged at 10000 rpm; the supernatant was decanted 
and the cell pellets were frozen and stored at –20 ˚C until use. 
 To determine if the human nNOS and eNOS holoenzymes can be expressed, the cell pellets 
were resuspended in MQW, given by the following equation: 
volume of water = (OD600)(100 µL)  
The samples were boiled prior to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). The protein expression was visually assessed from the change in the intensity of the bands 
at the expected protein size. 
 Because the human nNOSΔ290 and eNOSΔ66 holoenzymes have poly-histidine tags, His 
SpinTrap™ (GE Life Sciences) was used to purify the NOS proteins in the small scale. The cell 
pellets were lysed through freeze/thaw cycles. The samples were flash frozen in liquid nitrogen 
and thawed in an ice-water bath for 10 minutes; this process was repeated four times. The lysate 
was centrifuged at 10000 g for 10 minutes at 4 ˚C. The supernatant was loaded into the His 
SpinTrap™ column and the purification process proceeded as per the kit manual. Samples were 
taken from each wash step, and SDS-PAGE was performed to confirm protein expression and 
isolation. 
2.2.2.2 Large-scale growth for expression and purification 
 Once the appropriate E. coli strain was determined from the small-scale growth, 6 x 25 mL 
TB with respective antibiotics, i.e. ampicillin and chloramphenicol or ampicillin, chloramphenicol 
and tetracycline, in 250 mL flasks were inoculated with a single colony from selective agar plates. 
These starter cultures were incubated at 37 ˚C for 16 hours at 225 rpm. Then, 6 x 1 L TB with 
antibiotics were inoculated with 15 mL of each of the starter cultures. As above, the OD600 was 
monitored until approximately 1.0–1.2 and the culture was induced with 500 µM IPTG, 400 µM 
δ-aminolevulinic acid (δ-ALA), 500 µM adenosine 5’-triphosphate (ATP), 9.6 µg/mL 
FeSO4·7H2O, 2.4 µg/mL AlCl3·6H2O, 2.4 µg/mL MnCl2·H2O, 1.0 µg/mL CoCl2·6H2O, 0.5 µg/mL 
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ZnSO4·7H2O, 2.4 µg/mL NaMoO4·2H2O, 0.1 µg/mL CuCl2·H2O, 0.5 µg/mL H3BO3 and a pinch 
of riboflavin. The temperature was decreased to 25 ˚C and the cells were left to grow in the shaker 
for 40 hours at 225 rpm. After 40 hours, the cells were harvested via centrifugation at 6000 rpm 
for 10 minutes at 4 ˚C. The cell paste was flash froze in dry ice and stored at –80 ˚C until it was 
ready for purification. 
 The protocol detailed above was also applied to the large-scale growth of rat nNOS 
(pRnNOShisAmp) and bovine eNOS (pBeNOShisAmp) co-expressed with pGroESLChlor in 
BL21 (DE3) cells. Human iNOSΔ70 and mouse iNOS were both co-expressed with pCaMChlor 
in BL21 (DE3) cells. 
2.2.2.3 NOS holoenzyme purification 
 Frozen cells expressing the NOS holoenzyme were thawed and resuspended in four 
volumes of cold NOS Lysis Buffer, which consists of 40 mM Tris-HCl (pH 7.5 at 4 ˚C), 10% 
glycerol, 1 mM L-arginine, 3 mM ascorbic acid, 150 mM NaCl and 10 µM H4B and 1 mM 
phenylmethylsulfonyl fluoride (PMSF). The resuspended cells were lysed via homogenization 
using the Avestin EmulsiFlex-C5 homogenizer. One tablet of Roche cOmplete™ Mini EDTA-free 
was added per 50 mL of solution. The samples are centrifuged at 48000 g for 30 minutes at 4 ˚C. 
The supernatant were collected and the pellet was discarded. The supernatant was subjected to salt 
precipitation by adding (NH4)2SO4 to 65% concentration. To ensure efficient precipitation, the 
mixture was shaken vigorously for one hour at 4 ̊ C before centrifugation at 48000 g for 30 minutes 
at 4 ̊ C. The supernatant was discarded and the pellets were resuspended in cold ADP Wash Buffer, 
which contains 50 mM Tris-HCl (pH 7.5 at 4 ˚C), 10% glycerol, 100 µM L-arginine, 100 mM 
NaCl, 1 mM DTT and 0.1 mM PMSF. One cOmplete protease inhibitor tablet was added per 50 
mL of the resuspended pellet.  
 The resuspended pellet was further purified using the 2’ 5’ ADP Sepharose 4B column 
(Sigma), which is an affinity column that binds the NADPH binding site at the reductase domain 
of the NOS holoenzyme. Prior to loading the sample onto the column, it was regenerated by 3 
cycles of alternate washes with 3 column volumes of ADP Regeneration Solution 1 (0.1 M Tris-
HCl, pH 8.5 and 0.5 M NaCl) and 3 column volumes of ADP Regeneration Solution 2 (0.1 M 
NaOAc, pH 4.5 and 0.5 M NaCl). The ADP resin was equilibrated with at least 10 column volumes 
of the ADP Wash Buffer. 
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 The resuspended pellet was transferred into a 250 mL centrifuge bottle, and the equilibrated 
ADP resin was poured into the same bottle. This mixture was incubated on the rotisserie at 4 ˚C 
for 1 hour to maximize protein binding into the affinity column. After incubation, the protein-resin 
mixture was poured into a 1 cm x 30 cm Glass Econo-Column® (Bio-Rad). With the column 
stopcock in the “off” position, the mixture was left to sit at 4 ˚C for another 30 minutes. The 
stopcock was opened and the sample was allowed to flow through the resin. The ADP resin was 
washed with 5 column volumes of ADP Wash Buffer, followed by 5 column volumes of ADP Salt 
Wash Buffer (same as the ADP Wash Buffer but with 500 mM NaCl). The bound NOS proteins 
were eluted with 10 mL of 5 mM 2’ AMP dissolved in ADP Salt Wash Buffer. (Note that 2’ AMP 
is hard to dissolve and, hence, was left in a 37 ˚C water bath to increase its solubility.) Eluted 
fractions were collected at 1 mL volumes. 
 In cases where there was no observed binding to the 2’ 5’ ADP column, the CaM Sepharose 
4B resin was used. In this case, the precipitated pellet was resuspended in the CaM Wash Buffer 
(similar to the ADP Wash Buffer but contained 2 mM CaCl2). The resin-sample incubation 
procedure was the same. The samples were then washed with 5 column volumes of CaM Wash 
Buffer and eluted with the CaM Elution Buffer (ADP Wash Buffer with 4 mM EDTA).  
 The most concentrated fractions, which are yellow in colour, were pooled and were 
transferred into cellulose dialysis tubing (6000–8000 MWCO, Spectra/Por™) to be dialyzed 
against NOS Dialysis Buffer 1 (50 mM Tris-HCl [pH 7.5 at 4 ˚C], 10% glycerol, 5 µM L-arginine, 
3 mM ascorbic acid, 250 mM NaCl, 4 µM H4B, 1 mM DTT and 0.1 mM PMSF) for at least 3 
hours. Afterwards, the sample was dialyzed against NOS Dialysis Buffer 2 (same as NOS Dialysis 
Buffer 1 but with 100 mM NaCl) for at least 3 hours. 
 The protein yield was quantified via the UV-Vis spectra, taken at wavelengths from 300 to 






where Abs397 is the absorbance at 397 nm,  ε397  is the molar extinction coefficient at 397 nm 
(72 cm-1mM-1), and l is the path length (1 cm) (Ikuto et al. 1998). The absorbance at 450 nm 
(Abs450) was recorded as well, as it corresponds to the flavin content, i.e. cofactors, of the sample. 
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7.5% SDS-PAGE was run to assess the purity of the sample, as well as to verify the size of the 
purified protein. 
2.2.2.4 Active site analysis 
 The coordination status of the heme propionate at the substrate binding site, and thus the 
suitability of the enzyme for assays, is evaluated through ultraviolet (UV) visible spectra. The 
heme prosthetic group at the NOS active site has a characteristic UV absorbance at the Soret region 
that shifts either toward red or blue depending on the “oxidation, coordination and spin states of 
the heme iron,” which are then dependent on ligand binding and the electrostatic environment at 
the binding site.(Rousseau, Li, Couture, & Yeh, 2005) The UV absorbance spectra of NOS 
enzymes have similar shapes across bacterial and mammalian isoforms.(Montgomery, Dupont, 
Leivo, & Guillemette, 2010; Rousseau et al., 2005)  
 The unbound heme iron in the presence of water absorbs at a maximum at 420 nm, where 
it exists at a six-coordinated low-spin (6C LS) state.(Rousseau et al., 2005) When L-arginine and 
H4B are added, the heme iron moves into its preferred five-coordinated high spin (5C HS) state 
and the Soret peak shifts to 400 nm.(Rousseau et al., 2005) To confirm that the purified NOS is 
heme bound to the Cys ligand, addition of imidazole or carbon monoxide (CO) gas into the enzyme 
solution must cause a Soret peak shift at approximately 420 nm and 450 nm, 
respectively.(Rousseau et al., 2005) 
 UV-Vis spectroscopy was used, not only to quantify the purified protein, but also to verify 
that the heme at the NOS active site remains intact. Purified NOS holoenzymes were incubated 
with 10 mM H4B, 1 mM L-arginine and 1 mM imidazole on ice for 10 minutes. As a negative 
control, an equivalent volume of 50 mM Tris-HCl (pH 7.5 @ 4 ˚C) was added into the sample. 
The absorbance spectra of these samples were read from 350–550 nm using Cary® 5000 UV-Vis-
NIR (Varian). The absorbance values were normalized to the peak of the control sample. 
2.2.2.5 Flavin content analysis 
 To determine the FAD and FMN content of the purified NOS holoenzyme samples. Faeder 
and Siegel’s fluorimetric technique was performed with some modifications. In this method, 
excitation of FAD and FMN and 450 nm causes fluorescence at 535 nm. Standard curves were 
determined by measuring the fluorescence of FAD and FMN in concentrations varying from 10 to 
75 nM. 10 µM FAD and FMN stock solutions were made by dissolving pure FAD and FMN in 
standard buffer (0.1 M potassium phosphate, pH 7.7; 0.1 mM EDTA). Further dilutions were made 
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using the standard buffer as well. The stock and standard solutions were stored in tubes wrapped 
in aluminum foil to protect them from the light. 
 The Bradford assay was used to quantify the protein content of the NOS protein samples. 
The samples were then diluted into 50 nM concentrations in standard buffer to a final volume of 1 
mL. The diluted protein samples were boiled for 3 minutes and cooled rapidly on ice. To remove 
the proteins, the samples were centrifuged at 13000 rpm for 15 minutes. The supernatant was 
transferred into a fresh microfuge tube wrapped in aluminum foil. 
 Fluorescence measurements were performed using SpectraMax® Plus M5 Microplate 
Reader (Molecular Devices) at 27 ˚C. These experiments were performed using black (opaque) 
96-well plates. Each fluorescence reading at pH 7.7 was performed in triplicates at 100 µL 
volumes. Afterwards, a 10 µL volume was removed from each well and 10 µL of 0.1 M HCl was 
added. This brings down the pH of the solution to 2.6. Fluorescence was measured once again. 
 The concentration of diluted material is related to the intensity of fluorescence by the 
equation F = k[c], i.e. fluorescence intensity F equals the product of fluorescence constant k and 
concentration c. For FAD and FMN, Faeder and Siegel state that  
F = D [FAD] + N [FMN] 
where D and N are fluorescence constants of FAD and FMN, respectively.(Faeder & Siegel, 
1973) Furthermore, the pH of the solution affects the fluorescence of these flavins, and thus, 
their respective fluorescence constants. Hence, 
F .  = D .  [FAD] + N .  [FMN]  
F .  = D .  [FAD] + N .  [FMN] 
Once these constants are determined from the FAD and FMN standard curves, the above 
equations can be used to calculate the FAD and FMN content of the protein samples. 
2.2.3 Expression and purification of wild type CaM 
Electrocompetent BL21 (DE3) cells were transformed with pCaMChlor as in Section 
2.2.1.1. Starter cultures (25 mL LB broth with 45 µg/mL chloramphenicol) were inoculated with 
a single colony of CaM-expressing cells and were left to grow at 37 ˚C for 16 hours at 225 rpm. 6 
x 1 L LB with chloramphenicol were inoculated with 15 mL of the starter culture. The cell cultures 
were kept under the same conditions until OD600 reaches 0.6-0.8. Afterwards, CaM expression was 
induced by the addition of 500 mM IPTG per culture flask. Cells were harvested four hours after 
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induction via centrifugation at 6000 x g for 10 minutes at 4 ˚C. The cell pellets were flash frozen 
and stored at -80 ˚C. 
Cell pellets were resuspended in 4 volumes of CaM Buffer A (50 mM Tris-HCl, pH 7.5 @ 
4 ˚C; 1 mM CaCl2) with 100 mM NaCl and 1 mM DTT. The cells were lysed via homogenization. 
The samples were centrifuged at 48000 x g for 30 minutes at 4 ˚C. CaCl2 was added into the 
clarified supernatant to raise the calcium concentration to 5 mM. Ca2+ exposes the hydrophobic 
patches of CaM. The sample is loaded onto a 5 mL phenyl sepharose column (GE Life Sciences) 
via FPLC. Note that prior to loading the sample, this column was first equilibrated with Buffer A. 
After adding the sample, the column was washed by 5 column volumes of Buffer A. This 
was followed by 4 column volumes of CaM Buffer B (50 mM Tris-HCl, pH 7.5 @ 4˚C; 1 mM 
CaCl2; 500 mM NaCl). Then, the column was once again washed with Buffer A (2.5 column 
volumes). Afterwards, the bound CaM protein was eluted with CaM Buffer C (10 mM Tris-HCl, 
pH 7.5 @ 4˚C; 10 mM EDTA). 2 mL fractions were collected and the fractions with peaks at 2810 
nm, 277 nm and 215 nm were pooled and dialyzed against 1 L of Buffer A in two steps. 
The UV-Vis spectrum of the dialyzed sample was taken from 250-300 nm. The spectrum 
of purified CaM has a characteristic staircase shape that has a maximum at 277 nm. The absorbance 
at 277 nm was used to calculate the protein concentration using Beer’s Law and ε277 = 3029 M-1 
cm-1. If the concentration was less than 180 µM, then the sample was concentrated using 3K 
MCWO Millipore centrifugal concentrators. Samples were stored in 500 µL aliquots at -80 ˚C. 
The purified protein was verified using electrospray ionization mass spectrometry (ESI-MS). 
2.2.4 Oxyhemoglobin capture assay 
To assess the enzymatic activity of NOS enzymes, and consequently, the inhibitory activity 
of the NOS inhibitors, the rate of product formation, i.e. L-citrulline and/or NO production must 
be measured. A straightforward method is to use radiolabelled substrate, e.g. [3H]arginine, and 
then measure the amount of [3H]citrulline formed in solution over time. However, this method is 
labour intensive and produces a lot of radioactive waste. Fortunately, NO can react with certain 
compounds that render allows the NOS enzyme kinetics to be quantified spectrophotometrically. 
The oxyhemoglobin (oxyHb) capture assay exploits the reaction between NO and O2 bound 
to hemoglobin (Hb) to form ONOO- and methemoglobin (metHb) as shown below:(Hevel & 
Marletta, 1994) 
∙NO + oxyHb 
                 
⎯⎯⎯⎯⎯  ONOO- + metHb 
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OxyHb reacts with NO faster than unbound O2 and since one equivalent of NO reacts with one 
equivalent of oxyHb, NO production by the NOS enzyme can be monitored at initial rate 
conditions through a change in absorbance at 401 nm.(Hevel & Marletta, 1994) The difference in 
the absorbance of metHb and oxyHb at 401 nm (ΔAbs401 = Abs401(metHb) – Abs401(oxyHb)) directly 
correlates to the rate of NO formation.(Hevel & Marletta, 1994; Perdicakis, Montgomery, 
Guillemette, & Jervis, 2004) Under initial rate conditions, i.e. at less than 10% product 
formation, this assay allows for the direct assessment of the inhibitory activity of the NOS 
inhibitor when the substrate concentration is greater than the Michaelis constant Km.(Hevel & 
Marletta, 1994) 
2.2.4.1 Oxyhemoglobin preparation and calibration 
 Approximately 5 mL of loosely packed lyophilized bovine hemoglobin (Hb) was dissolved 
in the minimal amount of 50 mM Tris-HCl (pH 7.5 @ RT). Approximately 10–20 mg of Na2S2O4 
was added into the saturated Hb solution. Non-oxygenated Hb is dark brown in colour, but the 
addition of Na2S2O4 oxidizes it and turns the colour of the solution into “cherry” red. This oxidation 
can be verified through the absorbance spectra of the sample; the oxyHb spectrum shows a more 
pronounced local peaks at 530 and 576 nm compared to non-oxygenated Hb (Figure 2.1). The 
oxyHb solution was desalted using PD-10 Desalting Column (GE LifeSciences). The absorbance 
spectra of the purified oxyHb and the sample concentration was calculated, per the following 
equation: 
Equation 2.2 
[oxyHb] = [1.013(Abs576) −  0.369(Abs630) −  0.7353(Abs560)] × 100 × dilution factor 
The coefficients in the equation are in units of cm-1M-1, as published by Benesch et al. 1973. The 
multiplier 100 is a conversion factor, such that [oxyHb] is expressed in µM. Dilution of the sample 





Figure 2.1. Absorbance spectra of oxyhemoglobin (oxyHb) and methemoglobin (metHb). The absorbance spectra of 
hemoglobin (Hb) shows the characteristic Soret peak for heme proteins at about 401 nm. Furthermore, the presence 
of two local maxima at 530 nm and 575 nm indicates that the formation of oxyHb. The oxidation of the horse heart 
Hb with sodium dithionite yields a bright red solution (“cherry red”). Reduced Hb formed via the addition of ferrous 
cyanide is a reddish-brown solution. 
 As mentioned above, ΔAbs401 can be used to calculate the rate of NO synthesis. Hevel 
and Marletta reported that the molar extinction coefficient of Δε401 is approximately 60000 cm-
1M-1, suggesting that this assay is highly sensitive.(Hevel & Marletta, 1994) However, Δε401 
tends to vary per oxyHb solution, especially at high concentrations. Hence, it is necessary to 
perform calibration experiments per oxyHb preparation. 
 To calculate Δε401, standard curves were generated for both oxyHb and metHb (Figure 
2.2). The prepared oxyHb stock was diluted into 40 µM in 50 mM Tris-HCl (pH 7.5 @ RT). 
MetHb was generated by diluting 40 µM in 0.12 mM K3Fe(CN)6; this ferricyanide solution was 
made by dissolving the appropriate amount of solid K3Fe(CN)6 in 50 mM Tris-HCl (pH 7.5 @ 
RT). Using a 96-well plate reader, the oxyHb and metHb solutions were diluted two-fold from 
40 µM to 0.625 µM in 100 µL-volume triplicates. 100 µL of 50 mM Tris-HCl (pH 7.5 @ RT) 
and 0.12 mM K3Fe(CN)6 were used as blanks for baseline measurements of oxyHb and metHb. 
The difference ΔAbs401 = Abs401(metHb) – Abs401(oxyHb) was plotted against [Hb], and the slope of 




Figure 2.2. Sample oxyhemoglobin (oxyHb) calibration curve. The molar extinction coefficient of Abs401(metHb) – 
Abs401(oxyHb)  is given by the difference in slopes of the absorbance functions of oxyHb and metHb. This coefficient 
is used to convert the absorbance at 401 nm into moles of NO formed by the NOS enzyme from the L-arginine 
substrate. 
2.2.4.2 Determination of enzymatic activity and Km of NOS isozymes 
 The activity of NOS enzymes were quantitatively assessed via the oxyHb capture assay; 
the human NOS enzymes were compared to their mammalian counterparts. These experiments 
utilized 96-well plates and each reaction was performed in quadruplicates at 100 µL volumes. 
 For the activity assay, two different solutions were prepared prepared separately: the 
enzyme solution and the heme solution. The enzyme solution consists of 10 µM FAD, 10 µM 
FMN, 500 µM NADPH, 50 µM H4B, 100 µM DTT, 50 U/mL catalase, 100 U/mL superoxide 
dismutase (SOD), 0.2 mg/mL bovine serum albumin (BSA), and 10% glycerol in 50 mM Tris-
HCl (pH 7.5 @ RT). The amount of NOS added varied according to the isoform. The final 
concentration of nNOS, eNOS and iNOS were 30 nM, 70 nM and 28.5 nM, respectively; these 
values are the same for both human and mammalian NOS. CaM was diluted to 3 µM in 50 mM 
Tris-HCl (pH 7.5 @ RT) and 200 µM CaCl2 or 250 µM EDTA. The complete enzyme solution 
contains the NOS isozyme of interest, its co-factors and in the case of nNOS and eNOS, CaM. 
This mixture was incubated at RT for 2 minutes before the reaction initiation to allow maximum 
interaction between CaM and the NOS holoenzymes. 
 Each well was filled with 10 µL complete enzyme solution and NOS synthesis was 
initiated by adding 90 µL heme solution into it. The heme solution contains the substrate, L-
y = 0.0545x + 0.0502
R² = 0.9991
y = 0.0797x + 0.0816
R² = 0.9998
























arginine, and the NO-reporter, oxyHb. This solution was prepared such the final volume of 100 
µL contained 5 µM oxyHb, 25 µM L-arginine, 500 µM NADPH, 0.18 mg/mL BSA, 50 U/mL 
catalase, 100 U/mL SOD, 10% glycerol and either 200 µM CaCl2 or 250 µM EDTA in 50 mM 
Tris-HCl (pH 7.5 @ RT). Immediately after the addition of the heme solution, ΔAbs401 was 
obtained by measuring the Abs401 of reaction at RT over 5 minutes in 7-second intervals using 
SpectraMax® Plus 384 Microplate Reader (Molecular Devices). The ΔAbs401 was given in units 














NOS activity is expressed in terms of NO formed in nmol per minute per mg of protein (nmol 
NO min-1 mgP-1). 
 Kinetic parameters Km and Vmax for the L-arginine substrate were determined using the 
same protocol as above, only the final [L-arginine] was varied from 0.625 µM to 40 µM via two-
fold serial dilutions. Baseline measurements were taken using a heme solution that did not 
contain any L-arginine in it. Calculated rate of reactions (per Equation 3.2) were plotted against 
substrate concentrations and were fitted to a Michaelis-Menten curve using GraphPad Prism. 
2.3 Results and discussion 
2.3.1 Human nNOS holoenzyme  
2.3.1.1 pHnNOShisKan 
 As mentioned previously, the human nNOS holoenzyme has been successfully subcloned 
into a high-expression vector, PDS-78. pHnNOShisKan was expressed in both BL21 (DE3) and 




         
Figure 2.3. Small-scale expression of pHnNOShisKan in E. coli strains. (a) In BL21 (DE3) cells, there is no increase 
in intensity of bands corresponding to human nNOS holoenzyme (red box, 161 kDa) before and after induction 
(lanes 1-4 and lanes 5-8, respectively), especially relative to the GroEL bands (yellow box, 57 kDa). (b) There is an 
increase in human nNOS holoenzyme band intensity after induction (lanes 4-6) in BL21 (DE3) CodonPlus RP cells. 
GE High Molecular Weight Calibration Kit was used as ladders for both gels; weights are given in kDa. 
 In Figure 2.3a, the co-expression of GroES/EL serves as an internal control, so that the 
lack of change in band intensity for human nNOS holoenzyme indicates the lack of expression. 
This failure of expression could be due to either codon usage bias or the vector in use. However, 
since there was an observed change in band intensity in the BL21 (DE3) CodonPlus RP strain 
Figure 2.3b, this result can be attributed to the inability of the BL21 (DE3) strain to express the 
NOS protein. In this case, the NOS protein expression was induced via addition of IPTG. Indeed, 
the human nNOS holoenzyme sequence contains 61 instances of Arg rare codons (AGA, AGG, 
CGA and CGG) and 42 instances of Pro rare codon CCC. This mismatch could have hindered 
the human nNOS expression in the commonly used BL21 (DE3). 
 Since pHnNOShisKan can be expressed in BL21 (DE3) RP cells, large-scale growth and 
expression were commenced. The purification steps outlined were performed, but it did not yield 
any protein. 
 





































Figure 2.4. Purification of human nNOS holoenzyme from pHnNOShisKan expressed in BL21 (DE3) CodonPlus 
RP cells. Each lane represents stages of the purification process. From L-R: (1) Ladder, (2) Resuspended pellet, (3) 
ADP resin Flow-through, (4) ADP Wash, (5) ADP Salt Wash, (6) Eluted Fraction 1, (7) Eluted Fraction 2, and (8) 
Eluted Fraction 4. The human nNOS holoenzyme was present in the lysate, ADP Flow-through and ADP Wash. 
 NOS proteins usually elute from the 2’ 5’ ADP column starting from fractions 2–4. 
However, as seen on the gel in Figure 2.4, there were no bands that correspond to the size of 
human nNOS holoenzyme, though these were present in the lysate. The presence of the protein 
band in the column flow-through (and at roughly the same intensity as the lysate) suggests that 
the protein did not bind to the resin at all. This result was initially speculated to be due to 
possible protein aggregation from high expression, as well as the tendency of the nNOS PDZ 
domain to form inclusion bodies. However, the above results do not definitively lead to such 
conclusions. 
2.3.1.2 pHnNOSΔ290hisAmp 
 The truncated human nNOS sequence (nNOSΔ290) was successfully subcloned into the 
pCWori vector through ligation; the resulting 8422-bp plasmid is called pHnNOSΔ290hisAmp 
(Figure 2.5). A double digest of the plasmid with EcoRI and NdeI separates the vector from the 























Figure 2.5. Plasmid map of pHnNOSΔ290hisAmp. This plasmid contains the truncated human nNOS holoenzyme 
subcloned into pCWori via ligation. It is ampicillin-resistant and uses the moderate-expression promoter tac. 
Restriction enzymes EcoRI, NcoI and NdeI (noted above) were used to validate subcloning success. 
 
Figure 2.6. Analytical digests of the pHnNOSΔ290hisAmp construct. Single digest with either EcoRI (lane 2) or 
NdeI (lane 3) both yield fragments of approximately 8.4 kbp in length. Double digest with EcoRI and NdeI (lane 5) 
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results in 5.0 kbp and 3.4 kbp fragments, corresponding to the pCWori vector and nNOSΔ290 holoenzyme insert 
respectively.  
 Large-scale growth and expression followed for pHnNOSΔ290hisAmp in BL21 (DE3). 
Attempts to purify the protein using the 2’ 5’ ADP Sepharose 4B resin (Section 2.2.2.3) did not 
yield purified protein. However, when the CaM Sepharose 4B resin was used, purified protein 
was eluted. 
 
   
Figure 2.7. Purification of human nNOSΔ290 holoenzyme from pHnNOSΔ290hisAmp expressed in BL21 (DE3) 
CodonPlus RP using affinity columns. (a) 2’ 5’ ADP Sepharose resin, lanes: (1) ladder, (2) lysate, (3) resuspended 
pellet, (4) salt cut supernatant, (5) ADP column flow-through, (6) ADP wash, (7) ADP salt wash and (8-12) eluted 
fractions 1-5). (b) CaM Sepharose resin, lanes: (1) ladder, (2) lysate, (3) salt cut supernatant, (4) resuspended pellet, 
(5) CaM column flow-through, (6) CaM wash, (7) eluted fraction 4, (8) eluted fraction 8 and (9) pooled fractions. 
 Though Figure 2.7b shows that the protein is of size 120 kDa (10 Da less than expected), 
the UV-Vis spectra of the pooled fractions eluted from the CaM resin has the characteristic shape 
of NOS isozymes, which shows the Soret peak at approximately 397 nm (not shown, for details 
see Section 2.2.2.4). Hence, it was postulated that there must be a mutation in the NADPH 
binding site that prevents the human nNOS holoenzyme from binding to the ADP affinity resin. 
Recall that the unsuccessful purification of the human nNOS holoenzyme from pHnNOShisKan 
was previously attributed to aggregation. However, the results above, i.e. that the human nNOS 
holoenzyme can be purified using the CaM resin, suggests that the high-expression vector could 
still be worth trying. Perhaps, the CaM resin could be used to purify the human nNOS 
holoenzyme from pHnNOShisKan. 
 In any case, sequencing information show that pHnNOSΔ290hisAmp indeed contained 
mutations. These mutations were artifacts from the template used during the PCR amplification 
of the nNOSΔ290 insert sequence. Lee (2014) reported three single nucleotide mutations, all of 
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Table 2.5. Mutations found in the nNOSΔ290 insert sequence carried over into the pHnNOSΔ290hisAmp 
plasmid. The nucleotide and amino acid numbers correspond to their positions in the truncated sequence. 
Nucleotide change Amino acid mutation 
G → C (883) Glu295Gln 
G → T (1312) Gly438Trp 
G → A (3199) Gly1067Arg 
 
These mutations are absent in the original human nNOS holoenzyme (pHnNOS) plasmid 
obtained from Dr. Philip Marsden at the University of Toronto; these occurred spontaneously 
during the pHnNOShisKan subcloning process. The first two mutations were considered benign: 
Glu and Gln have similar structures, while the Gly438Trp mutation is a naturally occurring 
variant. There is no evidence shown that even though this mutation is within the CaM binding 
region, it does not interfere with the interaction between nNOS and CaM. Indeed, it was possible 
to purify the nNOSΔ290 holoenzyme using the CaM affinity resin, CaM Sepharose 4B.  
 However, the Gly1067Arg mutation proved to be problematic since it is within the 
NADPH binding region. As such, it decreased (or removed) the protein’s affinity toward the 2’ 
5’ ADP Sepharose resin that was used to purify NOS proteins. Furthermore, if it cannot bind 
NADPH, the enzymatic reaction cannot proceed because the electron transfer between the 
flavins cannot occur. 
 Two approaches were explored to reverse the Gly1607Arg mutation: (1) amplify the 
nNOS insert using the original plasmid pHnNOS as the template and ligate into pCWori, and (2) 
perform site-directed mutagenesis on the new plasmid pHnNOSΔ290hisAmp. Ultimately, the 
site-directed mutagenesis approach was the successful method. A full plasmid containing the 
correct phenotype Gly1607 was transformed into and extracted from DH5α E. coli cells. The 
PCR mixture components and program cycles were not optimized in the interest of time. A TD-
PCR was used so that multiple combinations of PCR components could be assessed 
concurrently, since the ideal annealing temperature depends on factors such as salt content, and 
DNA and oligonucleotide concentrations. 
 The success of mutation was assessed using restriction enzyme digests with NcoI, EcoRI 
and NcoI, and EcoRI and NdeI. The removal of one NcoI site in the pHnNOSΔ290hisAmp 





Figure 2.8. Simplified plasmid maps of pHnNOSΔ290hisAmp before (a) and after (b) site-directed mutagenesis. The 
successful mutant contains Gly1607 and lacks the NcoI cleavage site at position 3598. 
 Prior to site-directed mutagenesis, restriction digest by NcoI results in the formation of 
four fragments of lengths 5201 bp, 1523, 1467 bp and 231 bp. The removal of the NcoI 
restriction site downstream of the target mutation removes the smallest band, and the digest of 
pHnNOSΔ290hisAmp’ yields 5432 bp, 1523 bp and 1467 bp fragments. 
 
    
Figure 2.9. Analytical digests of successful pHnNOSΔ290hisAmp mutant, which lacks one NcoI restriction site. (a) 
Double digest with EcoRI and NdeI (lane 3) results in 5.0 kbp and 3.4 kbp fragments, corresponding to the pCWori 
vector and nNOSΔ290 holoenzyme insert respecitvely. (b) Single digest with NcoI shows that the ~250 bp band in 
the non-mutated plasmid (lane 1) is not present in the mutated plasmid (lane 2). Double digest with EcoRI and NcoI 
also shows that the ~250 band in the non-mutated plasmid (lane 4) was lost in the successful mutant, replaced by a 
~500 bp band. 0.5 µg of GeneRuler 1kb DNA Ladders was used for both gels (lanes 1 and 3, respectively). 
 Sequencing data corroborated the findings from the analytical digests above: Arg1607 






























random, suggesting that it was indeed a spontaneous mutation. No other mutations were found in 
the sequence. 
 
Figure 2.10. Purification of human nNOSΔ290 holoenzyme from pHnNOSΔ290hisAmp’ in BL21 (DE3) CodonPlus 
RP using the ADP Sepharose 4B resin. Each lane represents stages of the purification process. From L-R: (1) 
Ladder, (2) Lysate, (3) Salt cut supernatant, (4) Resuspended pellet, (5) ADP resin flow-through, (6) ADP Wash, (7) 
ADP Salt Wash, (8) Pooled fractions. 
 Figure 2.14 shows that the purified protein is approximately 130 kDa in size. The 
absorbance spectra of the pooled fraction has the expected shape and Soret peak at approximately 
397 nm (see Section 2.2.2.4 for more details). These results suggest that the correct truncated 
human nNOS holoenzyme was successfully expressed and purified. 
2.3.2 Human eNOS holoenzyme 
2.3.2.1 pHeNOShisKan 
 The human eNOS holoenzyme had been previously subcloned into the high-expression 
vector PDS-78. Hence, pHeNOShisKan was subject to small-scale growth and expression 
experiments to determine if the E. coli strain BL21 (DE3) was sufficient.  























Figure 2.11. Small-scale expression of pHeNOShisKan in E. coli strains. Lanes 1–3 corr+espond to samples before 
induction, while lanes 5–7 refer to samples after induction. Lanes 1 and 5 are BL21 (DE3) cells that express 
GroES/EL; lanes 2 and 5 are BL21 (DE3) cells that express both GroES/EL and pHeNOShisKan; lanes 3 and 7 are 
BL21 (DE3) CodonPlus RP cells that express pHeNOShisKan. There are no visually discernible differences in the 
band intensities that correspond to human eNOS holoenzyme among all three samples, before and after induction. In 
lieu of a molecular weight ladder, purified bovine eNOS (133 kDa) was used to estimate band sizes (lane 4). Red 
box = human eNOS holoenzyme; yellow = GroEL. 
 From the gel on Figure 2.11, it appears that the human eNOS holoenzyme was not 
expressed at all in either BL21 (DE3) or BL21 (DE3) CodonPlus RP strains. None of the expected 
eNOS holoenzyme bands have an increase in intensity comparable to that of the GroES/EL internal 
control. The human eNOS holoenzyme exhibits codon bias; there are 60 instances of rare Arg 
codons AGA, AGG, CGA and CGG, and 54 instances of the Pro rare codon CCC, in the sequence. 
Given the above results, it is not clear whether the BL21 (DE3) CodonPlus RP strain was able to 
mitigate this codon usage bias and express the eNOS enzyme. 
 Such results may also indicate that the addition of IPTG could not induce NOS expression 
via the T7 promoter, at least in the case of pHeNOShisKan (since it was shown in 
pHnNOShisKan). If the problem lies with the PDS-78 vector, then the human eNOS holoenzyme 
must be expressed using a different vector, perhaps pCWori. 
2.3.2.2 pHeNOSΔ66hisAmp 
 The truncated human eNOS sequences (eNOSΔ66) was also subcloned into the pCWori 
vector to produce the 8398-bp long plasmid pHeNOSΔ66hisAmp. The double digest reaction with 
EcoRI and NdeI yielded two fragments: 5.0 kbp and 3.4 kbp (Figure 2.13). 







Figure 2.12. Plasmid map of pHeNOSΔ66hisAmp. This plasmid contains the truncated human eNOS holoenzyme 
subcloned into pCWori via ligation. It is ampicillin-resistant and uses the moderate-expression promoter tac. 




Figure 2.13. Analytical digests of the pHeNOSΔ66hisAmp construct. Single digest with either EcoRI (lane 2) or 
NdeI (lane 3) both yield fragments of approximately 8.4 kbp in length. Double digest with EcoRI and NdeI (lane 5) 
results in 5.0 kbp and 3.4 kbp fragments, corresponding to the pCWori vector and eNOSΔ66 holoenzyme insert 
respectively.  
 There were no reported mutations in the heNOS template that was used to amplify the 
heNOSΔ66 holoenzyme insert. Sequencing data showed that no spontaneous mutations occurred 
during the subcloning process of pHeNOSΔ66hisAmp. Hence, no further genetic manipulations 
were applied to the plasmid. 
  BL21 (DE3) CodonPlus RP cells that express pHeNOSΔ66hisAmp were grown in the 
small scale and purified using the His SpinTrap™ (2.2.2.1). The human eNOS holoenzyme can be 





Figure 2.14. Purification of human eNOSΔ66 holoenzyme from pHeNOSΔ66hisAmp in BL21 (DE3) 
CodonPlus RP using ADP Sepharose 4B. Each lane represents stages of the purification process. From L-R: (1) 
Ladder, (2) Lysate, (3) Resuspended pellet, (4) Salt cut supernatant, (5) ADP resin flow-through, (6) ADP Wash, (7) 
ADP Salt Wash, (8-13) Collected fractions 2-7, (14) Pooled fractions.  
 The purified protein is approximately 130 kDa in size (Figure 2.14), which is the 
expected size for human eNOSΔ66 holoenzyme. The absorbance spectra of the pooled fractions 
showed a characteristic shape for NOS enzymes, including the Soret peak at about 397 nm. As 
such, it can be concluded that the expression and purification of the human eNOSΔ66 
holoenzyme was a success. 
2.3.3 NOS protein yields and purity 
 As mentioned above, this project aims to develop human constitutive NOS expression 
systems with yields comparable to that of well-established NOS expression systems. Table 2.6 
lists the highest recorded yields for all nNOS and eNOS purifications that were performed to 
obtain all NOS isozymes to be used for the duration of this project. The values are expressed in 
terms of nmol of protein per L of culture grown for 40 hours. 
Table 2.6. NOS holoenzyme yields calculated as moles per litre of culture. 
Isoform Organism E. coli strain nmol protein per L culture 
nNOS 
rat BL21 (DE3) 67 ± 14 
human BL21 (DE3) CodonPlus RP 7.7 ± 4.0 
eNOS 
bovine BL21 (DE3) 21 ± 1.4 















































The above values suggest that both human nNOS and eNOS holoenzyme have apparently lower 
yields than their mammalian counterparts. This discrepancy can be explained by the fact that the 
human NOS enzymes were expressed in BL21 (DE3) CodonPlus RP, which require three 
different antibiotics to maintain the selective pressure. Thus, these cells tend to grow more 
slowly than the BL21 (DE3) cells, which only needs one antibiotic (or two, if co-expressed with 
GroES/EL). Furthermore, the mammalian NOS were all co-expressed with GroES/EL, which 
stabilize the proteins’ native fold during growth and purification and thus, increasing protein 
yield. 
 
Figure 2.15. Purified human and non-human NOS holoenzymes in 7.5% SDS-PAGE. From L-R: (L) 
ladder, (1) rat nNOS, (2) human nNOS, (3) bovine eNOS, (4) human eNOS, (5) murine iNOS, (6) human 
iNOS.  
 As shown in Figure 2.15, the purified proteins vary in purity. This can be remedied by the 
addition of size exclusion chromatography in the purification process. However, this step 
requires the concentration of the eluted fractions into very small volumes, which then increases 
the risk of aggregation. Additionally, NOS is a highly unstable protein, such that further agitation 
may lead to protein misfolding and/or degradation. Though the presence of other proteins have 
negligible effects on kinetic assays, pure NOS proteins are still desired so that they can be used 
for other projects, especially those that involve structure determination such as X-ray 
crystallography. Further, a more pure sample can be used to study substrate and inhibitor binding 
kinetics using techniques such as isothermal calorimetry. 
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 The absorbance spectra of the purified human nNOS and eNOS holoenzymes have shapes 
similar to that of NOS isozymes with intact heme ligands (Figure 2.1). The spectra of NOS samples 
incubated with saturated imidazole show a distinct shift from about 397 nm to 420 nm. This change 
indicates that the heme ligand moved from the favourable five-coordinated high spin state to a six-
coordinate low spin state. Hence, the heme propionate remained bound to the active site Cys 
residue of the NOS holoenzymes and the purified samples were fit for enzymatic studies. Although 
these results are conclusive, it can be further verified by bubbling the sample with CO, which 
would cause the peak to shift towards 450 nm. CO bubbling was not performed, however. 
 Note that the addition of control and L-arginine treatments have mostly overlapping NOS 
Soret peaks at about 397 nm. This observation is due to the fact that the buffers used for NOS 
purification and storage contain L-arginine. Indeed, the samples all contain 5 µM L-arginine,which 
has been found to aid in the stabilization of NOS holoenzymes. However, the present results show 
that the addition of excess L-arginine (1 mM of substrate is orders of magnitude more than required 
for most assays) does not affect the NOS absorbance spectra in any significant way. Furthermore, 
the substrate-free NOS samples have been shown to have the Soret peak at around 400 nm instead 
of the expected 420 nm because the sample buffers contain different salts that could interfere with 
the heme. The 420 nm Soret peak could theoretically be observed in samples that are dissolved in 
pure water, but this would compromise the native fold of the protein. 
 Finally, 10 µM H4B was added to the samples as well and it caused protein aggregation, as 
evidenced by the increase in the turbidity of the sample. The spectra of these samples showed 
seemingly infinite increase in absorbance towards 300 nm (not shown). Recall that the pterin co-
factor binds NOS at the dimer interface and promote the dimer stability by enhancing hydrophobic 
interactions. While H4B is soluble in water at 10 µM, it can precipitate out of a solution that 
contains salts, such as the buffer in which NOS is stored. This could have driven the exposure of 




Figure 2.16. Absorbance spectra of purified NOS holoenzymes used in this project. The curves are 
normalized to the Soret peak of the control samples. Both human and mammalian NOS exhibit red-shifted 
Soret peaks from about 400 nm to 425 nm upon incubation with imidazole. 
2.3.5 Flavin content analysis 
 Table 2.7 lists how much flavin cofactors are present in the purified NOS proteins. In 
general, NOS protein samples showed a higher concentration of FMN than FAD. These values are 
similar for both human and non-human isoforms, with the exception of the human nNOS, which 
contains 2.5-fold higher concentrations of both FAD and FMN. This result could be a consequence 
of concentrating the sample using a centrifugal concentrator. The human nNOS sample was 































































This low concentration was not observed in the other purified NOS, so those samples were not 
concentrated before storage. However, using the centrifugal concentrators causes the denaturation 
and/or degradation of NOS proteins. The bound flavins FAD and FMN are likely to be released 
back into solution, such that the NOS sample now has higher mole of heme to mole of flavin ratios. 
Table 2.7 .Heme to flavin content ratio of purified samples determined via fluorescence. The values are 
expressed in terms of mole of flavin per mole of heme. 
Isoform Organism heme/FMN heme/FAD 
nNOS 
human  2.60 2.60 
rat  0.56 0.43 
eNOS 
human  0.46 0.44 
bovine  0.52 0.47 
iNOS 
human  0.55 0.51 
mouse  0.37 0.61 
 
2.3.6 Determining the kinetic parameters of human and non-human NOS holoenzymes 
 The L-arginine concentration of 25 µM was chosen as an appropriate concentration for 
steady-state activity assays. It is larger than the average Km value for human and non-human NOS 
by a factor of at least 10, at which point the Vmax would be reached. For these experiments, the 
measured activity in units of nmol NO min-1 mgP-1 were normalized against the activity of the 
non-human NOS with Ca2+ treatments. The relative activities are reported in the following figures. 
 
Figure 2.17. Relative activity of human and rat nNOS holoenzymes at 25 µM L-arginine. These values 
were normalized using the activity of rat nNOS with or Ca2+ (27 ± 5.1 nmol NO min-1 mgP-1) as 100%. 
Non-parametric Mann-Whitney U Test for independent samples show that there is no significant 
difference in activity between rat and human nNOS (p = 0.281), as well as the difference in activity of 




Figure 2.18. Relative activity of bovine and human eNOS holoenzymes at 25 µM L-arginine. These 
values were normalized using the activity of bovine eNOS with or Ca2+ (76 ± 2.5 nmol NO min-1 mgP-1) 
as 100%. Non-parametric Mann-Whitney U Test for independent samples show that there is no 
significant difference in activity between bovine and human eNOS (p = 0.551), but the difference in 
activity of eNOS in the presence and absence of Ca2+ is statistically significant (p < 0.001) 
 
Figure 2.19. Relative activity of murine and human iNOS holoenzymes at 25 µM L-arginine. These 
values were normalized using the activity of murine iNOS with or Ca2+ (170 ± 46 nmol NO min-1 mgP-
1) as 100%. Non-parametric Mann-Whitney U Test for independent samples show that there is no 
significant difference in activity between murine and human iNOS (p = 0.328), as well as the difference 
in activity of iNOS in the presence and absence of Ca2+ (p = 0.645). 
 Statistical analyses were performed using a sample size of 6 for each treatment. A non-
parametric test, Mann-Whitney U Test, was used because normality tests (from GraphPad) state 
that the samples do not have a normal distribution. As shown in the figures above, the both human 
and non-human cNOS have significantly low activity when EDTA is added to remove Ca2+ ions. 
This mechanism confirms the calcium-dependent CaM activation of cNOS. In the presence of 
Ca2+, the human nNOS showed a significantly higher activity than the rat nNOS, at an 
approximately 300% increase. On the other hand, there is no significant difference observed 
between human and bovine eNOS. Meanwhile, the presence or absence of Ca2+ does not 
significantly affect both human and murine iNOS; the measured activities for both EDTA and Ca2+ 
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treatments are all apparently equivalent. This result agrees with the fact that iNOS activity is 
independent of calcium concentration.  
 Following the above results, NO production rates for each NOS isoform were used to 
obtain Michaelis-Menten curves, Km and Vmax values (Figure 2.20). In particular, Vmax values are 
consistent with the steady-state activity assay results above. Km and Vmax values were calculated 
such that the Michaelis-Menten model fit gives R2 values of greater than 0.90. These are compared 
against literature values (Table 2.8). Note, however, that the literature values were the kinetic 
parameters reported by different groups studying NOS enzymes. As mentioned previously, these 
values were not obtained using a standardized protein expression methods. For instance, Gross et 
al. performed NOS activity assays using crude lysates, which may have contain elements that could 
have interfered with the activity measurements. Indeed, there exist multiple entries for the same 
NOS isoform from the same organism, as listed on BRENDA. 
 
Figure 2.20. Michaelis-Menten plots of human and non-human NOS holoenzymes for the substrate L-
arginine. (a) Combined plot of all NOS isoforms used in this study shows how the Michaelis-Menten 
curves look relative to each other. Separate plots with human (blue) and non-human (red) NOS are shown 
for (b) nNOS, (c) eNOS and (d) iNOS. The calculated Km and Vmax values are summarized in Table 2.8. 
 
a 
b c d 
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Table 2.8. Km and Vmax values for human and non-human NOS holoenzymes. 
Isoform Organism 












human 1300 ± 61 1.5 ± 0.20 90a, 400b, 1000c 1.6a,r 
rat 170 ± 12 1.2 ± 0.28 9.8d, 120-170e, 284b, 
940-960f 
1.3r, 2-2.8e, 14-18d 
eNOS 
human 26 ± 2.4 1.5 ± 0.41 0.90a, 19g, 142h 0.9a, 3.9g, 4.4h 
bovine 58 ± 4.3 2.4 ± 0.47 31i, 143j, 340-350k 1.7r, 2.1j 
iNOS 
human 360 ± 31 5.9 ± 0.90 22l, 290a 2.2a, 16s, 22t 
murine 170 ± 11 2.2 ± 0.33 170-815m, 1006n, 
1100o,p, 1620q 
2.8n, 14-18q 
The above listed literature values for Vmax and Km were determined using purified proteins from either tissue 
extracts or heterologous expression in yeast or bacteria. 
a Garvey, Furfine, & Sherman, 1996. bFang et al., 2009. cDemady, Jianmongkol, Vuletich, Bender, & Osawa, 2001. 
dHiki, Hattori, Kawai, & Yui, 1992. eSchmidt, Smith, Nakane, & Murad, 1992. fBredt & Snyder, 1990 gLeber et al., 
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 In a comprehensive review of NOS mechanism, Santolini summarized the global kinetic 
model of NOS catalysis. Computer simulations showed that the final product of NOS activity is 
not radical NO per se, but rather, the Fe(III)-NO complex.(Santolini, 2011; Stuehr et al., 2004) 
According to the model, NO synthesis is governed by three main kinetic parameters: kr (reduction 
of Fe(III) at the heme), kox (oxidation of Fe(II)-NO to form peroxynitrite) and kd (dissociation of 
NO from Fe(III) heme). The balance between kr, kox and kd determine whether NO will be released 
into solution (productive cycle) or remain bound to the heme (futile cycle). Set points for these 
parameters have been determined experimentally, which were then used to develop the global 
catalytic model. Furthermore, kr has been shown to depend on the NOS reductase, while kox and 
kd are determined by the NOS oxygenase. These values are specific to the NOS isoform and as 
such, account for the differences in their catalytic activities and kinetic parameters. Using NOS 
chimeras, Wang et al. determined that kr values must have evolved optimally relative to kd, which 
is determined by the distal heme pocket residues. Bulky residues such as Ile blocks NO release 
more effectively than small residues like Val. Indeed, they have shown that increasing kr resulted 
in a decrease in kd without further manipulating the distal heme pocket. From fastest to slowest, kr 
values are ranked as nNOS > iNOS > eNOS; kox, iNOS > eNOS > nNOS; and kd, nNOS > eNOS 
> iNOS. Taken together, these values determine the rank for the NOS synthesis rates: iNOS > 
nNOS >> eNOS. This ranking is consistent with the expected and observed Vmax values for non-
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human NOS but not for human NOS: nNOS > iNOS >> eNOS (Table 2.8). Given these results, it 
is worth noting that the kinetic parameter rankings were obtained using rat nNOS instead of human 
nNOS (Wang et al. 2016). Hence, it appears that kr, kox and kd values do not only vary between 
isoforms but across organisms as well. 
 Fang et al. (2009) attribute the discrepancies in Vmax values between isoforms to the 
difficulty in quantifying exact NOS enzyme concentrations, such that the activity were 
miscalculated. However, it is clear in their study and multiple others (including this one) that 
human nNOS tend to have higher activity than rat nNOS. On the other hand, both published and 
observed data show that bovine eNOS exhibit higher activity than human eNOS. While literature 
values suggest that murine iNOS has higher activity than human iNOS, our experimental values 
show the opposite. 
 The observed Michaelis-Menten constants agree with the expected values, as well as the 
relative affinities of non-human NOS isoforms with their human counterparts. However, the 
observed Km for human eNOS was higher than the observed Km for bovine eNOS; this is the 
opposite of literature Km values. This observation emphasizes the need for a standardized 
expression and assay systems for determining the kinetic parameters of NOS isoforms. 
Additionally, because these Km values are to be used further in the inhibition assays (for calculating 
Ki), this discrepancy may affect the observed isoform-selectivity of NOS inhibitors. These 
deviations are especially important with regard to the active site inhibitors because the affinity of 
L-arginine to NOS determines how well they can displace the substrate and inhibit catalysis. 
2.4 Conclusions 
 As discussed in Chapter 1, this project aims to develop expression systems for human 
cNOS holoenzymes. The process involves the verification of the published enzymatic activity and 
kinetic parameters associated with these proteins. The human nNOS and eNOS holoenzyme gene 
sequences were successfully cloned into pCWori, which is a commonly used vector for 
heterologously expressed heme-based oxygenases. The active site heme of these proteins were 
verified via UV-Vis and the full-length human NOS exhibited the expected Soret peak shifts 
characteristic of NOS. 
 The human NOS were further characterized using oxyhemoglobin capture assays. 
Although the steady-state NO synthesis activity of human eNOS and human iNOS are comparable 
to their non-human counterparts, human nNOS exhibited a significantly higher activity relative to 
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the rat nNOS. The maximum rates of reaction Vmax reflect this prior result. However, the relative 
NOS activities vary between human and non-human NOS. The human NOS ranking (fast to slow) 
is nNOS > iNOS >> eNOS, whereas for the non-human NOS, it is iNOS > nNOS >> eNOS. In 
term of Km, the relative affinities of the human NOS to L-arginine match up with those of the non-
human NOS. However, the human eNOS was observed to have a lower Km, i.e. higher affinity, 
than the bovine eNOS; this was the opposite of what was expected per published values. As 
previously mentioned, before this project, there is no published study using a standardized assay 
to determine the kinetic parameters for NOS activity. Our results provide a valid argument for the 
re-examination of first generation NOS inhibitors using human NOS because the kinetic 





3. Inhibition of human and non-human NOS holoenzymes 
3.1 Introduction 
 Maintenance of eNOS activity while blocking the target NOS isoform (either nNOS and 
iNOS) is paramount to the development of NOS inhibitors. However, NOS isoforms are highly 
conserved; the high homology among the isoforms hinders the development of isoform-selective 
drugs. Furthermore, structure-based drug design was not possible until recently, such that high-
throughput screening of lead compounds is very difficult. As mentioned above, high resolution 
crystal structures of the human NOS isozymes were not available until recently, owing to the 
highly unstable and highly dynamic nature of the full-length holoenzymes. Hence, drug 
development studies were performed using the more readily available non-human isoforms: rat 
nNOS and bovine eNOS. 
 As discussed in Chapter 1, there exist slight structural differences between human NOS 
and their non-human counterparts. As shown in Chapter 2, these differences affect NOS activity 
and its affinity towards the substrate L-arginine. This chapter discusses the effects of the 
differences between human and non-human isoforms on the inhibitory activity of early generation 
active site and CaM-binding inhibitors. 
3.1.1 Active site inhibitors 
 Since the active site inhibitors examined in this project are first generation compounds, 
they are not as complex as the most recently developed compounds. However, some have exhibited 
isoform selectivity by exploiting not only the differences in isoform structure, but also the 
differences in the active site binding kinetics. 
3.1.1.1 L-arginine analogues: L-NMMA, L-ALA and L-NNA 
 The earliest compounds tested for NOS inhibition are L-arginine analogues, usually with a 
functional group substitution at a guanidino nitrogen. Two of these compounds (L-NMMA and L-
ALA) contain hydrocarbon groups attached to a terminal guanidino nitrogen ( 
Figure 3.1). These compounds are all able to competitively displace L-arginine at the NOS active 
site but do not exhibit selectivity for any of the NOS isoforms. These small molecules share a 
similar mechanism of action. They inactivate NOS by modifying the heme at the active site. Using 
stopped-flow spectroscopy and UV-Vis, Zhang et al. show that when these compounds bind, the 
aromatic heme gets reduced.(Zhang et al., 1997) The loss of aromaticity corresponds to the 
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observed loss of the Soret peak at approximately 400 nm. The inhibitory effect of L-NMMA and 
L-ALA is time-dependent because the heme inactivation is preceded by enzyme mediated 
oxidation and hydroxylation of the inhibitors. In a mechanism reported by Zhang et al., an alkylic 
radical from either inhibitor forms an adduct with the heme.(Zhang et al., 1997) Furthermore, both 
L-NMMA and L-ALA undergo hydroxylation such that L-citrulline and NO are still formed; the 
guanidino group provides the proton for NO cleavage to proceed. However, the alkylated heme is 
now unable to coordinate Fe, rendering the NOS enzyme inactive ( 
Figure 3.2b). 
 
Figure 3.1. L-arginine and derivatives. 
 L-NMMA and L-ALA are anchored to the NOS active site with the same interactions as 
that of L-arginine. Additionally, the substituted alkyl group juts into binding pockets near the 
active site (Figure 3.3a). Apparently, these moieties do not quite extend towards the possible 
isoform-specific binding sites. Indeed, these compounds have been found to be non-selective. 
 
Figure 3.2. Structures of (a) intact heme, (b) inactivated heme via allylation from L-ALA and (c) 




Figure 3.3. L-arginine analogues at the NOS active site. (a) L-ALA at the rat nNOS active site (PDB: 
1K2S). (b) L-NNA at the bovine eNOS active site (PDB: 8NSE). 
 On the other hand, L-NNA does not inactivate the NOS heme. It binds NOS at a higher 
affinity than the substrate L-arginine (nM versus µM range, respectively). This increase in affinity 
is attributed to the additional H-bonds formed by the nitrate group with the active site backbones 
(Figure 3.3b). Unlike L-NMMA and L-ALA, L-NNA exhibits selectivity toward nNOS and eNOS 
over iNOS. This isoform-selectivity is due to the fast turnover at the iNOS active site. L-NNA has 
slow off-rates for cNOS. Consequently, L-NNA is considered a time-dependent inhibitor. NOS 
pre-incubated with L-NNA showed lower NO synthesis rates than NOS that were not pre-
incubated.(Furfine, Harmon, Faith, & Garvey, 1993) 
3.1.1.2 Cyclic aromatic inhibitors: 3-bromo-7-nitroindazole and 1400W 
 Since simply modifying L-arginine does not promote isoform selectivity, cyclic bulky 
compounds like 3-bromo-7-nitroindazole and 1400W were developed. The bulkiness allow these 
compounds to access binding sites that may be unique to one isoform. Like the L-arginine 
analogues, these compounds contain moieties that mimic the guanidino group of the substrate and 
interact with the heme via π-stacking.  
 3-bromo-7-nitroindazole (3Br7NI) was the most potent nitroindazole derivative developed 
as a NOS inhibitor. It is a competitive reversible NOS inhibitor that was originally thought to be 
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that 3Br7NI only has modest selectivity towards nNOS over eNOS. 3Br7NI was found to be unable 
to enter endothelial cells to affect eNOS. The selectivity of this compound is determined by the 
tissue distribution of NOS isoforms.(Rosenfeld et al., 2002) 
 The nitro group draws electron density away from the indazole. Hence, in addition to 
stacking interactions, 3Br7NI is anchored to the active site via electrostatic interactions. Unlike 
the L-arginine analogues, however, 3BrNI does not form H-bonds with the invariant Glu residue 
at the active site.(Raman et al., 2001) Crystal structures reveal that 3Br7NI bind differently 
between cNOS and iNOS; 3Br7NI was found to bind cNOS at the H4B binding site in addition to 
the active site. Futhermore, it can displace previously bound H4B, where it has partial π-stacking 
with Trp447.(Raman et al., 2001) 
 
Figure 3.4. Selective NOS inhibitors 3-bromo-7-nitroindazole and 1400W. 
Lastly, 1400W is an irreversible inhibitor of iNOS. This isoform selectivity can be 
attributed to the conformational changes at the active site upon binding as well as the kinetics of 
NOS catalysis. The crystal structure of murine iNOS complexed with 1400W reveals that 1400W 
has two binding modes for iNOS. This conformational flexibility of the iNOS active site, compared 
to cNOS, partly explains the isoform selectivity.(Fedorov, Hartmann, Ghosh, Schlichting, & 
Carolina, 2003) The aromatic ring of 1400W has π-stacking interactions with the heme. 
Meanwhile, the aminomethyl group forms H-bonds with the conserved Tyr485 and H4B. Further, 
the amidine forms H-bonds with the invariant Glu371. These interactions, particularly the latter, 
cause a helical shift driven by hydrophobic interactions that is not possible in nNOS due to the 
presence of the Tyr hydroxyl (equivalent to Phe in iNOS, Leu in eNOS). With 1400W oriented as 
such, the heme inactivation mechanism proceeds very rapidly in iNOS. 
The heme inactivation mechanism of 1400Wis different from that of L-NMMA and L-
NNA, as there is no formation of an inhibitor-heme adduct.(Li, Raman, Marta, Masters, & Poulos, 
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2001) 1400W cannot act as a substrate like L-NMMA and L-ALA because it lacks a proton to 
donate to the heme-bound peroxide (See the mechanism on Figure 1.5b). Consequently, there is 
no L-citrulline and NO produced.(Li et al., 2001) The resulting peroxide-heme complex gets 
degraded into biliverdin IX, in an irreversible reaction (Figure 3.2c). The fast rate of kinetic 
turnover of iNOS allows this reaction to proceed much faster in iNOS compared to nNOS and 
cNOS, the difference in enzyme kinetics and structural differences make 1400W an effective 
iNOS-selective inhibitor. 
3.1.2 CaM-binding inhibitors 
 As mentioned before, CaM binds and activates approximately 300 other proteins. Hence, 
using CaM-binding inhibitors poses the risk of off-target inhibition, not only of eNOS but also of 
other unrelated proteins. Despite this, compounds such as mastoparan and monobutylin trichloride 
have been reported to block nNOS activity.(Curtin et al., 2015) The calmodulin binding sequences 
of human NOS have 100% homology with their non-human counterparts. As such, one would 
expect that the treatment of, say, human eNOS and bovine eNOS with a CaM-binding inhibitor 
would yield similar IC50s. CaM-binding inhibitors have been studied in the last 20 years, 
alongside active site NOS inhibitors. The compounds target either CaM itself or the CaM-binding 
sequences within the NOS proteins. In this chapter, inhibitors of the first kind trifluoperazine (TFP) 
and melatonin are examined (Figure 3.5). Inhibition studies with TFP and melatonin may provide 
insight on NOS activation by CaM, and if there are differences in human and non-human NOS. 
 





 TFP is a phenothiazine-based antipsychotic compound that has been used to treat 
schizophrenia.(Vandonselaar, Hickie, Quail, & Delbaere, 1994) Its pharmacological effects 
include blocking adrenaline and dopamine receptors in brain neurons. Additionally, TFP also acts 
as a CaM inhibitor.(Mata et al., 2015) TFP binding to CaM gas been shown to have a negative 
effect on the activation of other CaM-dependent proteins such as troponin. Lee and Stull reported 
that TFP completely inhibits NOS activity at concentrations ranging from 200 µM – 1 mM.(S. Lee 
& Stull, 1998) 
 TFP binding to CaM requires at least three occupied Ca2+-binding sites.(Vandonselaar et 
al., 1994) As discussed earlier, Ca2+-binding exposes hydrophobic patches that bind NOS. TFP 
binds at these very sites, thereby preventing NOS binding and activation. The CaM linker helix 
that separates the C and N-lobes is further split into two smaller helices upon TFP binding, such 
that CaM is unable to bind NOS.(Koevesi, Menyhard, Laberge, & Fidy, 2008) Despite multiple 
published crystal structures, the correct binding stoichiometry is yet to be solved; previous studies 
reported that 2-7 TFP molecules bind per CaM. In any case, it was reported that TFP exhibits anti-
cooperative binding, i.e. binding of more TFP molecules diminishes its affinity. Its binding 
constant Kd was observed to be between 1-8 µM.(Vandonselaar et al., 1994) 
3.1.2.2 Melatonin 
 Melatonin is a ubiquitous signalling molecule in mammals and other organisms that is 
responsible for the regulation of circadian and seasonal rhythms. Endogenous melatonin is 
synthesized at the pineal gland, although experiments using anti-melatonin antibodies have shown 
that there are extrapineal melatonin sources.(Acuña et al., 2014) In particular, melatonin-
synthesizing enzyme have been found in immune cells and endothelial cells. Interestingly, the 
concentrations of melatonin at night were sufficient to significantly inhibit nNOS, especially since 
they exceed the Kd of approximately 10 µM (Mukherjee et al., 2014; Turjanski et al., 2004)  
 Like TFP, melatonin also requires CaM to be Ca2+ before it can bind the protein.(Benitez-
King, Huerto-Delgadillo, & Anton-Tay, 1993; Turjanski et al., 2004) Consequently, it also 
interacts with the hydrophobic patches in CaM. Furthermore, the structures obtained from NMR 
and molecular docking experiments show that melatonin-bound CaM resembles TFP-bound CaM. 





3.2.1 Ki determination assays 
 For the active site inhibitors, the inhibition assays were performed using the 
oxyhemogloblin capture assay as described in Section 2.2.4 with a few modifications. Prior to the 
addition of the heme solution to initiate the reactions (with 5 µM L-arginine), 10 µL of enzyme 
solution containing NOS and CaM were incubated with the appropriate inhibitor concentration for 
10 minutes at room temperature. The concentration of inhibitors were varied from 10-5 to 1 mM. 
In general, the inhibitors were dissolved in water; however, 3-bromo-7-nitroindazole is insoluble 
in water and was thus dissolved in DMSO. For each inhibitor concentration, NOS response was 
measured as the rate of reaction as a percentage of the maximum rate when there is no inhibitor 
present. NOS response was plotted against the log concentration of inhibitors; the inhibition 
response curves were fitted and IC50s were obtained using GraphPad. The Ki values for each 







where [S] is the concentration of L-arginine added in solution. For CaM-binding inhibitors, the 
concentration of CaM was also varied (750 nM to 3 µM). To calculate the Ki values of TFP and 
melatonin, the same equation is used but [S] is the concentration of CaM and Km is the dissociation 
constant Kd values from NOS peptide binding studies: 5.6 nM for nNOS, 1.6 for eNOS and 3.3 for 
iNOS (Wu, Berta, & Tsai, 2011). These NOS peptides correspond to the CaM binding peptides 
(Figure 1.2). Note that the human CaM binding sequences are 100% homologous with their non-
human counterparts, so the same values are used for each isoform. 
3.3 Results and discussion 
3.3.1 Active site inhibitors 
 As discussed above, the L-arginine analogues L-NMMA and L-ALA do not exhibit 
isoform selectivity over eNOS, though previous studies have shown that they have a lower affinity 
towards murine iNOS.(Olken & Marletta, 1992; Reif & McCreedy, 1995; Zhang et al., 1997) 
Indeed, a similar trend was observed in L-NMMA inhibition studies (Figure 3.6). Furthermore, 
the relative affinities of human NOS towards L-NMMA agree with that of the non-human NOS: 
(highest to lowest affinity) eNOS > nNOS >> iNOS. However, it is worth noting that the Ki values 
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for human nNOS and eNOS were an order of magnitude less than rat nNOS and bovine eNOS, 
respectively. Meanwhile, the inhibition assays for L-ALA showed a larger difference in the order 
of magnitude of the Ki values for human NOS compared to non-human NOS (Figure 3.7). Such 
differences translate to a change in the relative affinity ranking: eNOS > nNOS >> iNOS for non-
human NOS and eNOS > iNOS > nNOS for human NOS. Given that both L-NMMA and L-ALA 
exhibit the highest affinity towards eNOS over nNOS and iNOS, these inhibition assays agree with 
previous research that both compounds cannot be used clinically as NOS inhibitors. 
 Recall that L-NNA has been shown to be non-selective in vitro, though Ki values suggest 
that it has modest selectivity over iNOS.(Nam et al., 1998; Reif & McCreedy, 1995) The relative 
affinity for the non-human NOS is nNOS > eNOS ~ iNOS; human NOS, nNOS ~ eNOS > iNOS 
(Figure 3.8). As with L-ALA, the ranking for L-NNA is not preserved between human and non-
human NOS. Of particular interest are the Ki values for human nNOS and eNOS, which are very 
similar within two significant digits. As such, it is an unsuitable candidate for clinical use, as 
previous research would suggest. 
 The dose-inhibition curves for 3Br7NI are very tight, which corresponds to Ki values that 
are not only in the same order of magnitude but are very similar (Figure 3.9). Consequently, the 
relative affinity for both human and non-human NOS are similar as well: nNOS ~ eNOS ~ iNOS. 
This suggests that 3Br7NI is not at all selective in vitro, agreeing with the current consensus. To 
verify if the tissue-dependent nNOS selectivity observed for L-NNA using mice, further tests (in 
vivo or ex vivo) must be performed. 
 As shown in Figure 3.10, 1400W shows considerable selectivity towards iNOS for both 
human and non-human NOS. Furthermore, the Ki values for eNOS are several orders of magnitude 
larger than nNOS and iNOS. As well, the relative affinity ranking for both human and non-human 
NOS agree with each other: iNOS >> nNOS >> eNOS, which is consistent with previously 
published data.(Garvey et al., 1997) However, it is worth noting that the observed values were a 
result of one assay run with quadruplicate samples. Hence, standard errors were not obtained and 




















Figure 3.6. Dose-inhibition curves for L-NMMA in the presence of 5 µM L-arginine after 10 mins of pre-
incubation. Calculated Ki values for each isoform are listed on the right. aKi values obtained from (Reif & 
McCreedy, 1995). nd stands for no data. 
 
Figure 3.7. Dose-inhibition curves for L-ALA in the presence of 5 µM L-arginine after 10 mins of pre-
incubation. Calculated Ki values for each isoform are listed on the right. bKi from (Zhang et al., 1997). cKi 
from (Olken & Marletta, 1992). nd stands for no data. 
 
Figure 3.8. Dose-inhibition curves for L-NNA in the presence of 5 µM L-arginine after 10 mins of pre-
incubation. Calculated Ki values for each isoform are listed on the right. aKi values from Reif and 
Isoform Obs. Ki, µM Lit. Ki, µM 
HnNOS 0.79 ± 0.74 nd 
RnNOS 1.3 ± 0.24 0.65a 
HeNOS 0.074 ± 016 0.70a 
BeNOS 0.18 ± 0.089 nd 
HiNOS 4.11 ± 0.19 nd 
iNOS 4.28 ± 0.12 3.9a 
 
Isoform Obs. Ki, µM Lit. Ki, µM 
HnNOS 13 ± 0.11 nd 
RnNOS 1.9 ± 0.025 0.47a 
HeNOS 0.075 ± 0.19 nd 
BeNOS 0.26 ± 0.013 nd 
HiNOS 3.0 ± 0.10 nd 
MiNOS 240 ± 0.14 3.4b 
 
Isoform Obs. Ki, µM Lit. Ki, µM 
HnNOS 0.11 ± 0.11 nd 
RnNOS 0.018 ± 0.036 0.09a 
HeNOS 0.11 ± 0.14 0.02a 
BeNOS 2.9 ± 0.21 1.5b 
HiNOS 3.9 ± 0.17 nd 




McCreedy (1995).(Reif & McCreedy, 1995) bKi values from Nam et al. (1998).(Nam et al., 1998) nd 
stands for no data. 
 
Figure 3.9. Dose-inhbition curves for 3-bromo-7-nitroindazole in the presence of 5 µM L-arginine after 
10 mins of pre-incubation. Calculated Ki and IC50 values for each isoform are listed on the right.aKi 













Figure 3.10. Dose-inhibition curves for 1400W in the presence of 5 µM L-arginine after 10 mins of pre-
incubation. Calculated Ki values for each isoform are listed on the right. aKi values from (Garvey et al., 
1997). nd stands for no data. 
3.3.2 CaM-binding inhibitors 
 The CaM-binding inhibitors require Ca2+-occupied EF hands; the inhibition assays were 
performed under saturated Ca2+ concentrations, while varying the concentration of the inhibitors. 
Figure 3.11 shows the dose-inhibition curves for TFP at a constant L-arginine concentration of 5 
µM. Because the curves exhibit a sigmoidal decay characteristic of inhibitors and because it is 
known that TFP does not bind the NOS active site, it can be said that TFP acts as an allosteric 
inhibitor of NOS. The calculated IC50 values are all within the same order of magnitude for both 
human and non-human NOS. For all NOS, the inhibition effect can only be observed at higher 
concentrations of TFP. Recall that Lee and Stull reported that it takes 200 µM to 1 mM of TFP to 
Isoform Obs. Ki, µM Obs. IC50, µM Lit. IC50, µM 
HnNOS 5.4 ± 0.23 0.023 nd 
RnNOS 4.4 ± 0.10 0.022 0.17a 
HeNOS 4.9 ± 0.14 0.021 nd 
BeNOS 15 ± 0.13 0.046 0.86a 
HiNOS 10 ± 0.31 0.019 nd 
MiNOS 4.6 ± 031 0.015 0.29a 
 
Isoform Obs. Ki, µM Lit. Ki, µM 
HnNOS 13 ± 0.49 2.0a 
RnNOS 7.6 ± 0.26 nd 
HeNOS 1100 ± 0.017 50a 
BeNOS 350 ± 0.27 nd 
HiNOS 0.55 ± 0.15 0.5a 




inhibit NOS activity. Furthermore, there is no observed isoform selectivity.(S. Lee & Stull, 1998) 
Indeed, iNOS are also inhibited at similar concentrations, albeit at the higher end of the range.This 
result is expected since TFP binds the CaM molecule itself and not the NOS isoform. It is worth 
noting, however, that these experiments were performed in excess CaM and Ca2+ so the effect of 
TFP may be masked. 
 To further assess NOS inhibition by TFP, CaM concentrations were varied for nNOS and 
eNOS. (Recall that iNOS are co-expressed with CaM and so varying [CaM] is not possible for this 
isoform.) Figure 3.12a shows the dose-inhibition curves of human and non-human nNOS at 
varying CaM concentrations. In general, the inhibition curves at lower CaM concentrations are 
shifted to the right, implying an increase in IC50. Meanwhile, the inhibition curves for eNOS 
exhibit an opposite trend (Figure 3.12b). At lower CaM concentrations, the inhibition curves are 
shifted to the left, i.e. the IC50s decreased. At this point, however, the effect of CaM is not 
conclusive; inhibition curves at lower CaM concentrations need to be obtained as well. Further, 
the effect of Ca2+, especially at physiological conditions (225 nM), will have to be assessed. 
 
Figure 3.11. Dose-inhibition curves for TFP in the presence of 5 µM L-arginine after 10 mins of pre-
incubation. Calculated IC50s and Ki values for each isoform are listed on the right. 
Isoform Obs. IC50, µM Obs. Ki, µM 
HnNOS 0.12 0.075 
RnNOS 0.30 0.19 
HeNOS 0.27 0.095 
BeNOS 0.25 0.087 
HiNOS 0.98 0.52 






Figure 3.12. Dose-inhibition curves of (a) nNOS and (b) eNOS for TFP at varying CaM concentrations 
(750 nM to 3 µM CaM). Solid lines refer to human cNOS and dotted lines refer to non-human cNOS. (c) 
Ki values of TFP for each NOS isoform. 
 
 The effect of incubation time on TFP inhibition of NOS was also assessed, by adding TFP 
directly into the NOS enzyme solution before preincubation with CaM. (Note that the NOS enzyme 
solution needs to be preincubated with CaM to ensure that NOS is bound to CaM). It was observed 
that the addition of TFP in the absence of CaM causes precipitates to form; the clear yellow NOS 
enzyme solution, which contains the flavin cofactors, turned opaque when TFP was added. 
However, there was no NOS activity observed upon the addition of L-arginine to initiate the 
reaction. Attempts to optimize the incubation time assays are under way, including preincubating 
the TFP in the CaM solution instead of the NOS solution. The ratio of [NOS enzyme] to [CaM] 
and the ratio of [CaM] to [TFP] will also be assessed. 
 Meanwhile, the CaM-binding inhibitor melatonin showed no inhibitory effect under 
conditions used for active site inhibitors. Figure 3.13 shows that there is no apparent inhibition by 
melatonin for all NOS. However, it must be noted that here, melatonin was added after the 

















formed when melatonin was added. The results shown here agree with the fact that melatonin can 
only bind Ca2+-bound CaM but not apoCaM or CaM in complex with NOS. To circumvent this, 
melatonin was added to the NOS enzyme solution at the same time as CaM. However, as with 
TFP, precipitates formed and no NOS activity was observed.  
 
Figure 3.13. Dose-inhibition curves for melatonin in the presence of 5 µM L-arginine after 10 mins of 
preincubation.  
3.4 Conclusions 
 As Boer et al. report, the selectivity of NOS inhibitors can be evaluated by taking the ratio 
of Ki values.(Boer et al., 2000) Table 3.1 summarizes the observed selectivity (or non-selectivity) 
for active site inhibitors discussed above. Since these ratios are calculated with eNOS Ki values as 
denominators, the most selective inhibitor must have small non-zero values. Indeed, as mentioned 
above, 1400W exhibits selectivity toward iNOS (and nNOS) over eNOS for both human and non-
human NOS. In general, none of the other inhibitors (except L-NNA for non-human NOS) 
exhibited selectivity according to this metric. In fact, most ratios give large numbers, suggesting 
low Ki values or high affinity for eNOS. These results mean that these inhibitors cannot be used 
clinically due to off-target inhibition of eNOS. It is also worth noting that there exist differences 
in these ratios between human and non-human NOS, suggesting that the relative selectivity vary 
between them as well. Indeed, this was discussed previously with regard to the affinity rankings. 
These observations then lend validity to our earlier claim that the structural differences in human 
and non-human NOS lead to differences in the isoform selectivity of early active site inhibitors. 
However, these findings need to be further verified by performing more assay runs to obtain 
sample means for statistical analyses of these apparent differences in inhibitor selectivity. 
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Table 3.1. Ratio of observed Ki values for active site inhibitors.  
human non-human  
n/e i/e n/e i/e 
L-NMMA 11 56 7.2 24 
L-ALA 180 40 7.2 870 
L-NNA 0.95 34 0.006* 3.7 
3Br7NI 1.1 2.1 0.29* 0.31* 
1400W 0.012* 0.001* 0.022* 0.001* 
 *These values infer selectivity. 
 Meanwhile, the preliminary experiments with CaM-binding inhibitors TFP and melatonin 
show that these do not exhibit isoform-selectivity as expected. Further experiments featuring 
changes in CaM and Ca2+ concentrations, as well as variable incubation times, are to be performed 





4. Summary and future work 
 Chapter 2 describes the development of heterologous expression systems for human 
constitutive NOS holoenzymes. Human nNOS and eNOS sequences were successfully cloned and 
expressed in E. coli. The purification of these human NOS were similar to that of non-human NOS 
in the lab. However, the yield was lower than that of non-human NOS. In any case, assessment of 
the active site heme via UV-Vis and activity assays via oxyhemoglobin capture have produced 
expected results. In particular, the Michaelis-Menten constants Km that were determined for each 
NOS isoform is consistent with previously published values. However, it is worth noting that the 
purified NOS proteins are not “clean,” i.e. the sample contains other unwanted proteins as 
evidenced by the extra bands in the SDS-PAGE gels. Consequently, other assays that could 
corroborate the calculated Km values such as the binding assay isothermal calorimetry could not 
be performed using the aforementioned protein samples. Hence, it would be beneficial to improve 
expression and purification protocols to ensure qualitatively and quantitatively better yields for the 
human NOS holoenzymes. For example, assays to optimize the storage buffer components may be 
performed. Note that the proteins were purified and stored in a monovalent buffer Tris, but perhaps 
using HEPES and MOPS would be appropriate. Certainly a good expression system would 
encourage the use human NOS instead of the more convenient rat nNOS and bovine eNOS. 
 Chapter 3 describes whether there is a difference in the isoform selectivity of NOS 
inhibitors between human and non-human NOS. Preliminary experiments showed that the relative 
affinities of the active site inhibitors, as given by the ratios of Ki values per isoform, mostly differ 
between human and non-human NOS, with the exception of 1400W. Unlike the others, 1400W 
showed significant selectivity towards iNOS for both human and non-human NOS, as described 
in previously published studies. It is worth noting, of course, that these inhibition assays are merely 
the first step in determining the differences in the interactions of inhibitors with human NOS versus 
their non-human counterparts. Structural studies such as x-ray crystallography and molecular 
docking simulations are necessary in pinpointing which specific structural features differ between 
human and non-human NOS when bound to these inhibitors.  
 CaM-binding inhibitors were also examined to determine if there is a difference in human 
and non-human NOS. The results of these assays would provide insight in the activation of NOS 
by CaM. In addition to the planned assays where CaM and calcium concentrations are to be varied, 
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experiments where incubation time with these inhibitors could be performed to determine whether 
human and non-human NOS are affected by these factors similarly. Furthermore, assays that 
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Appendix A – Truncated human NOS 
 The human nNOS and eNOS sequences were truncated at the C-terminal, such that the 
reductase domain only consists of the FMN binding site. Note that these sequences were also 
truncated at the N-terminal end to improve purification yields. The subcloning process was the 
same as the protocol detailed on Section 2.2.1. The oxyFMN sequences were generated via PCR 
using the following primers: 
Table A1. Forward and reverse primers (FP and RP) for PCR amplification of truncated human nNOS 
and eNOS with GC content and melting temperatures (Tm). Highlighted sequences correspond to the 
restriction sites for NcoI (cyan), NdeI (yellow) and EcoRI (green). 
Primer Sequence GC Tma 
hnNOSΔ290FP 5’ CCACCATGGTCATATGGGAAAACAGTCCCCCACAAAGAATGGC 3' 51.2% 75.9 ˚C 
hnNOSoxyFMNRP 5’ GCGGAATTCTTAATCTCCCACACAGAAGACATCACA 3’ 44.4% 71.8 ˚C 
heNOSΔ66FP 5’ CCACCATGGTCATATGCCCAAGTTCCCTCGTGTGAAGAACTGG 3’ 53.5% 76.1 ˚C 
heNOSoxyFMNRP 5’ GCGGAATTCTTAATCCTCTCCCACACAGAAGGTCTCACA 3’ 48.7% 73.8 ˚C 
a Tm values were calculated with the primer concentration at 0.5 µM, [NaCl] at 0 mM, [MgCl2] at 2 mM and 
[dNTPs] at 200 µM using the IDT OligoAnalyzer®. 
 
 Analytical digests were performed to verify subcloning success. Results from restriction 
enzymes experiments were corroborated by nucleotide sequences aligned with corresponding 
entries on the GenBank database. 
 
Figure A1. Analytical digests of successful pHnNOSoxyFMN (6973 bp) and pHeNOSoxyFMN (6934 bp) constructs. 
Lanes from L-R: (1) Ladder, (2) pHnNOSoxyFMN no enzyme control, (3) pHnNOSoxyFMN EcoRI single digest, (4) 
pHnNOSoxyFMN NdeI single digest, (5) pHnNOSoxyFMN EcoRI and NdeI double digest, (6) pHeNOSoxyFMN no 
enzyme control, (7) pHeNOSoxyFMN EcoRI single digest, (8) pHeNOSoxyFMN NdeI single digest, (9) 
pHeNOSoxyFMN EcoRI and NdeI double digest. Because the plasmid lengths are approximately the same size, the 
fragment lengths appear similar on the gel. Single digests yield fragments of 7.0 kbp; double digests, 5.0 and 2.0 





Figure A2. Plasmid map of pHnNOSoxyFMN. This plasmid contains the truncated human nNOS oxyFMN sequence 
subcloned into pCWori via ligation. It is ampicillin-resistant and uses the moderate-expression promoter tac. 




Figure A3. Plasmid map of pHeNOSoxyFMN. This plasmid contains the truncated human eNOS oxyFMN sequence 
subcloned into pCWori via ligation. It is ampicillin-resistant and uses the moderate-expression promoter tac. 
Restriction enzymes EcoRI and NdeI were used to validate the subcloning process. 
 
 The nNOSoxyFMN and eNOSoxyFMN proteins are expressed in E. coli BL21 (DE3) cells 
under the same growth conditions as described in Section 2.2.2.2. However, since the chaperone 
proteins GroES and GroEL were not co-expressed, ATP was not added into the media upon 
induction.  
 The cell pellets expressing nNOSoxyFMN or eNOSoxyFMN were resuspended in four 
column volumes of NOS Lysis Buffer (40 mM Tris-HCl, pH 7.5 @ 4 ˚C, 10% glycerol, 150 mM 
NaCl, 1 mM L-arginine, 1 mM PMSF). One tablet of cOmplete EDTA-free protease inhibitor was 
added per 1 L growth worth of cell pellet. The cells were lysed via homogenization. The samples 
were then centrifuged at 48000 x g for 30 minutes at 4 ˚C. 
 While the samples were spinning, 20 mL of Ni2+-NTA resin, which binds His-tagged 
proteins, was recharged with two column volumes of 100 mM NiSO4. The resin was washed with 
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10 column volumes of Milli-Q® water, followed by 10 column volumes of His Binding Buffer 
(NOS Lysis Buffer with 5 mM imidazole). The packed resin was resuspended after equilibration 
and then poured directly into the clarified supernatant. The resin-protein mixture was mixed in the 
rotisserie for 1 hour at 4 ˚C for maximal protein binding. Afterwards, the mixture was poured into 
a 1 cm x 30 cm Glass Econo-Column® (Bio-Rad) and was left to incubate at 4 ˚C for 30 minutes 
with the stopcock closed. Once the sample has flowed through the resin, it was washed with 5 
column volumes of the His Binding Buffer. Then, the resin was 5 column volumes of the His Wash 
Buffer (NOS Lysis Buffer with 20 mM imidazole) to remove non-specifically bound proteins. The 
bound proteins were eluted with His Elution Buffer (NOS Lysis Buffer with 200 mM imidazole); 
1 mL fractions were collected.  
 The most concentrated fractions, which were yellow in colour, were concentrated into a 
final volume of approximately 2 mL using a 30K MWCO Vivaspin® 6 centrifugal concentrator. 
This concentrated sample was loaded onto the HiLoad 16/60 Sephadex 200 (GE Life Sciences) for 
size exclusion chromatography via FPLC. Gel Filtration Buffer (50 mM Tris-HCl, pH 7.5 @ 4 ˚C, 
10% glycerol, 250 mM NaCl, 5 µM L-arginine, 1 mM DTT and 0.1 mM PMSF) was used as the 
running buffer. 1 mL fractions were collected. The absorbance at wavelengths 280 nm, 398 nm 
and 425 nm were monitored, and most concentrated fractions were pooled. Aliquots were flash 
frozen and stored at –80 ˚C. 
 To quantify the protein yield, the UV-Vis spectra of the pooled sample was read from 300 
to 700 nm. The Soret peak absorbance was plugged into Equation 2.1 to calculate the protein 
concentration in mM. The purity of the protein sample was assessed via 7.5% SDS-PAGE. The 
active site heme was assessed as described in Section 2.2.2.4. The flavin content of the sample was 




Appendix B – Calcium-deficient CaM mutant 
The CaM sequence containing the aforementioned mutations was obtained from Invitrogen. This 
452-bp sequence contains an upstream NcoI and a downstream BamHI restriction sites, allowing 
it to be cloned into pET9d (4308 bp) using the protocols outlined in Section 2.2.1. The successful 
construct, referred to as pCaM1234DNKan were verified via restriction enzyme digest and DNA 
sequencing. The CaM1234 plasmids were expressed in E. coli BL21 (DE3) as described in Section 
2.2.2.  
 
Table B1. Analytical digest of successful pCaM1234DNKan construct (4754 bp). Lanes from L-R: (1) GeneRuler 1 
kb DNA Ladder, (2) no enzyme control, (3) BamHI single digest, (4) NcoI single digest, (5) BamHI and NcoI 
double digest and (6) GeneRuler 100 bp DNA Ladder. Single digests yield fragments of about 5.0 kbp; double 





Table B2. . Plasmid map of pCaM1234DNKan. This plasmid contains the truncated apoCaM mutant sequence 
subcloned into pET9d  via ligation. It is kanamycin-resistant and uses the high-expression promoter T7. Restriction 




Appendix C – NOS and CaM DNA sequences 
 
pHnNOShisAmp (p537) – Human nNOSΔ290 holoenzyme with N-terminal polyhistidine tag in pCWori, 
























Protein sequence alignment of nNOS (GenPept: P29475.2; Query) and nNOS holoenzyme 
(Sbjct) aligned using NCBI BLAST. 
 
Query  289  GKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHAR  348 
            GKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHAR 
Sbjct  1    GKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHAR   60 
 
Query  349  RPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIY  408 
            RPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIY 
Sbjct  61   RPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIY  120 
 
Query  409  GAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFP  468 
            GAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFP 
Sbjct  121  GAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFP  180 
 
Query  469  QRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLL  528 
            QRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLL 
Sbjct  181  QRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLL  240 
 
Query  529  LQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACP  588 
            LQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACP 
Sbjct  241  LQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACP  300 
 
Query  589  FSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQS  648 
            FSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQS 
Sbjct  301  FSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQS  360 
 
Query  649  DKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPS  708 
            DKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPS 
Sbjct  361  DKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPS  420 
 
Query  709  FEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATET  768 
            FEYQPDPWNTHVWKGTN TPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATET 
Sbjct  421  FEYQPDPWNTHVWKGTNWTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATET  480 
 
Query  769  GKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGC  828 
            GKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGC 
Sbjct  481  GKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGC  540 
 
Query  829  ALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFG  888 
            ALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFG 
Sbjct  541  ALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFG  600 
 
Query  889  LGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFC  948 
            LGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFC 
Sbjct  601  LGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFC  660 
 
Query  949  VGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNL 1008 
            VGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNL 
Sbjct  661  VGDDVNIEKANNSLISNDRSWKRNKFRLTFVAEAPELTQGLSNVHKKRVSAARLLSRQNL  720 
 
Query  1009 QSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKV 1068 
            QSPKSSRSTIFVRLHTNGSQELQYQPGDHLGVFPGNHEDLVNALIERLEDAPPVNQMVKV 





nNOS holoenzyme alignment (cont’d – 2) 
 
Query  1069 ELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQ 1128 
            ELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQ 
Sbjct  781  ELLEERNTALGVISNWTDELRLPPCTIFQAFKYYLDITTPPTPLQLQQFASLATSEKEKQ 840 
 
Query  1129 RLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDM 1188 
            RLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDM 
Sbjct  841  RLLVLSKGLQEYEEWKWGKNPTIVEVLEEFPSIQMPATLLLTQLSLLQPRYYSISSSPDM  900 
 
Query  1189 YPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVP 1248 
            YPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVP 
Sbjct  901  YPDEVHLTVAIVSYRTRDGEGPIHHGVCSSWLNRIQADELVPCFVRGAPSFHLPRNPQVP  960 
 
Query  1249 CILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKG 1308 
            CILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKG 
Sbjct  961  CILVGPGTGIAPFRSFWQQRQFDIQHKGMNPCPMVLVFGCRQSKIDHIYREETLQAKNKG 1020 
 
Query  1309 VFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQ 1368 
            VFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQ 
Sbjct  1021 VFRELYTAYSREPDKPKKYVQDILQEQLAESVYRALKEQGGHIYVCGDVTMAADVLKAIQ 1080 
 
Query  1369 RIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDT 1428 
            RIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDT 
Sbjct  1081 RIMTQQGKLSAEDAGVFISRMRDDNRYHEDIFGVTLRTYEVTNRLRSESIAFIEESKKDT 1140 
 
Query  1429 DEVFSS 1434 
            DEVFSS 





pHeNOShisAmp (p536) – Human eNOSΔ66 holoenzyme with N-terminal polyhistidine tag in 


























Protein sequence alignment of eNOS (GenPept: P29474.3; Query) and eNOS holoenzyme 
(Sbjct) aligned using NCBI BLAST. 
 
Query  66   PKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLS  125 
            PKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLS 
Sbjct  1    PKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLS   60 
 
Query  126  QARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCV  185 
            QARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCV 
Sbjct  61   QARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCV  120 
 
Query  186  GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN  245 
            GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN 
Sbjct  121  GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN  180 
 
Query  246  SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL  305 
            SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL 
Sbjct  181  SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL  240 
 
Query  306  PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR  365 
            PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR 
Sbjct  241  PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR  300 
 
Query  366  NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA  425 
            NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA 
Sbjct  301  NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA  360 
 
Query  426  SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA  485 
            SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA 
Sbjct  361  SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA  420 
 
Query  486  KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA  545 
            KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA 
Sbjct  421  KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA  480 
 
Query  546  FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ  605 
            FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ 
Sbjct  481  FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ  540 
 
Query  606  HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR  665 
            HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR 
Sbjct  541  HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR  600 
 
Query  666  AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFS  725 
            AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFS 
Sbjct  601  AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAARDIFS  660 
 
Query  726  PKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDT  785 
            PKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDT 
Sbjct  661  PKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILVRLDT  720 
 
Query  786  GGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWV  845 
            GGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPPPGWV 





eNOS holoenzyme alignment (cont’d – 2) 
 
Query  846  RDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKW  905 
            RDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKW 
Sbjct  781  RDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYEEWKW  840 
 
Query  906  FRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQ  965 
            FRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQ 
Sbjct  841  FRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLAYRTQ  900 
 
Query  966  DGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFW 1025 
            DGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFW 
Sbjct  901  DGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPFRGFW  960 
 
Query  1026 QERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPK 1085 
            QERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPK 
Sbjct  961  QERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREPDNPK 1020 
 
Query  1086 TYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDV 1145 
            TYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDV 
Sbjct  1021 TYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDEAGDV 1080 
 
Query  1146  IGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP  1203 
             IGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTNSP 





 Analytical digests were performed to verify subcloning success. Results from restriction 
enzymes experiments were corroborated by nucleotide sequences aligned with corresponding 
entries on the GenBank database. 
 
Table B3. Analytical digests of successful pHnNOSoxyFMN (6973 bp) and pHeNOSoxyFMN (6934 bp) constructs. 
Lanes from L-R: (1) Ladder, (2) pHnNOSoxyFMN no enzyme control, (3) pHnNOSoxyFMN EcoRI single digest, (4) 
pHnNOSoxyFMN NdeI single digest, (5) pHnNOSoxyFMN EcoRI and NdeI double digest, (6) pHeNOSoxyFMN no 
enzyme control, (7) pHeNOSoxyFMN EcoRI single digest, (8) pHeNOSoxyFMN NdeI single digest, (9) 
pHeNOSoxyFMN EcoRI and NdeI double digest. Because the plasmid lengths are approximately the same size, the 
fragment lengths appear similar on the gel. Single digests yield fragments of 7.0 kbp; double digests, 5.0 and 2.0 





Table B4. Plasmid map of pHnNOSoxyFMN. This plasmid contains the truncated human nNOS oxyFMN sequence 
subcloned into pCWori via ligation. It is ampicillin-resistant and uses the moderate-expression promoter tac. 




pHnNOSoxyFMNhisAmp (p541) – Human nNOSΔ290 oxyFMN with N-terminal polyhistidine tag in 
















Protein sequence alignment of nNOS (GenPept: P29475.2; Query) and nNOSoxyFMN 
(Sbjct) aligned using NCBI BLAST. 
Query  289  GKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHAR  348 
            GKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHAR 
Sbjct  1    GKQSPTKNGSPSKCPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHAR  60 
 
Query  349  RPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIY  408 
            RPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIY 
Sbjct  61   RPEDVRTKGQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIY  120 
 
Query  409  GAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFP  468 
            GAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFP 
Sbjct  121  GAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFP  180 
 
Query  469  QRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLL  528 
            QRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLL 
Sbjct  181  QRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLL  240 
 
Query  529  LQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACP  588 
            LQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGL+FSACP 
Sbjct  241  LQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLQFSACP  300 
 
Query  589  FSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQS  648 
            FSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQS 
Sbjct  301  FSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQS  360 
 
Query  649  DKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPS  708 
            DKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPS 
Sbjct  361  DKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPS  420 
 
Query  709  FEYQPDPWNTHVWKGTNGTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATET  768 
            FEYQPDPWNTHVWKGTN TPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATET 
Sbjct  421  FEYQPDPWNTHVWKGTNWTPTKRRAIGFKKLAEAVKFSAKLMGQAMAKRVKATILYATET  480 
 
Query  769  GKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGC  828 
            GKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGC 
Sbjct  481  GKSQAYAKTLCEIFKHAFDAKVMSMEEYDIVHLEHETLVLVVTSTFGNGDPPENGEKFGC  540 
 
Query  829  ALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFG  888 
            ALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFG 
Sbjct  541  ALMEMRHPNSVQEERKSYKVRFNSVSSYSDSQKSSGDGPDLRDNFESAGPLANVRFSVFG  600 
 
Query  889  LGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFC  948 
            LGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFC 
Sbjct  601  LGSRAYPHFCAFGHAVDTLLEELGGERILKMREGDELCGQEEAFRTWAKKVFKAACDVFC  660 
 
Query  949  VGD  951 
            VGD 
Sbjct  661  VGD  663 





Table B5. Plasmid map of pHeNOSoxyFMN. This plasmid contains the truncated human eNOS oxyFMN sequence 
subcloned into pCWori via ligation. It is ampicillin-resistant and uses the moderate-expression promoter tac. 





pHeNOSoxyFMNhisAmp (p535) – Human eNOSΔ66 oxyFMN with N-terminal polyhistidine tag in 















Protein sequence alignment of eNOS (GenPept: P29474.3; Query) and eNOSoxyFMN 
(Sbjct) aligned using NCBI BLAST.  
Query  66   PKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLS  125 
            PKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLS 
Sbjct  4    PKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPEQLLS  183 
 
Query  126  QARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCV  185 
            QARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCV 
Sbjct  184  QARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNAPRCV  363 
 
Query  186  GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN  245 
            GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN 
Sbjct  364  GRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDFRIWN  543 
 
Query  246  SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL  305 
            SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL 
Sbjct  544  SQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPELFLL  723 
 
Query  306  PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR  365 
            PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR 
Sbjct  724  PPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTEIGTR  903 
 
Query  366  NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA  425 
            NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA 
Sbjct  904  NLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHHAATA  
1083 
 
Query  426  SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA  485 
            SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA 
Sbjct  1084 SFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWKGSAA  
1263 
 
Query  486  KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA  545 
            KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA 
Sbjct  1264 KGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRLFRKA  
1443 
 
Query  546  FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ  605 
            FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ 
Sbjct  1444 FDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSPRPEQ 1623 
 
Query  606  HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR  665 
            HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR 
Sbjct  1624 HKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFCAFAR 1803 
 
Query  666  AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGED  715 
            AVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGED 




pCaM1234DNKan (p542) – CaM1234DN in pET9d, cloned between NcoI and BamHI. Mutations 
relative to PubMed sequence AAA40864.1: D20N, D56N, D93N and D129N. 
 
 
Protein sequence alignment of CaM (GenPept: AAA40864.1; Query) and CaM1234DN 
(Sbjct) aligned using NCBI BLAST. 
Query  1    MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADG  60 
            MADQLTEEQIAEFKEAFSLF+KDGDGTITTKELGTVMRSLGQNPTEAELQDMINEV+ADG 
Sbjct  1    MADQLTEEQIAEFKEAFSLFNKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVNADG  60 
 
Query  61   NGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDE  120 
            NGTIDFPEFLTMMARKMKDTDSEEEIREAFRVF+KDGNGYISAAELRHVMTNLGEKLTDE 
Sbjct  61   NGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFNKDGNGYISAAELRHVMTNLGEKLTDE  120 
 
Query  121  EVDEMIREADIDGDGQVNYEEFVQMMTAK  150 
            EVDEMIREA+IDGDGQVNYEEFVQMMTAK 
Sbjct  121  EVDEMIREANIDGDGQVNYEEFVQMMTAK  150 
 
